1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
----------------
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission file number 0-27588
VITALCOM INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 3662 33-0538926
- ------------------------------- ----------------------------- ----------------------
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification Number)
15222 Del Amo Avenue
Tustin, California 92780
(714) 546-0147
- -------------------------------------------------------------------------------
(Address and telephone number of principal executive offices)
Securities registered pursuant to Section 12(b) of the Act:
- -------------------------------------------------------------------------------
None
Securities registered pursuant to Section 12(g) of the Act:
- -------------------------------------------------------------------------------
Common Stock, Par Value $0.0001 Per Share
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or any amendment to
this Form 10-K. [X]
The aggregate market value of the stock held by non-affiliates of the
Registrant, based upon the closing sale price of the Common Stock on March 15,
2000 as reported on the Nasdaq Small Cap Market, was approximately $8,572,019.
Shares of Common Stock held by each officer and director and by each person who
owns 5% or more of the outstanding Common Stock have been excluded in that such
persons may be deemed to be affiliates. This determination of affiliate status
is not necessarily a conclusive determination for other purposes.
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of March 15, 2000, there were 7,978,596 shares outstanding of the
issuer's common stock.
================================================================================
2
VITALCOM INC.
TABLE OF CONTENTS
Page
----
PART I
Item 1. Business 3
Item 2. Properties 11
Item 3. Legal Proceedings 11
Item 4. Submission of Matters to a Vote of Security Holders 11
PART II
Item 5. Market for the Registrant's Common Equity and
Related Stockholder Matters 12
Item 6. Selected Financial Data 13
Item 7. Management's Discussion and Analysis of
Results of Operations and Financial Condition 14
Item 7A. Quantitative and Qualitative Disclosures About
Market Risk 21
Item 8. Financial Statements and Supplementary Data 21
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure 21
PART III
Item 10. Directors and Executive Officers of the Registrant 34
Item 11. Executive Compensation 36
Item 12. Security Ownership of Certain Beneficial
Owners and Management 38
Item 13. Certain Relationships and Related Transactions 39
PART IV
Item 14. Exhibits, Financial Statement Schedules, and
Reports on Form 8-K 40
Signatures 42
2
3
PART I
CERTAIN STATEMENTS CONTAINED IN THIS ANNUAL REPORT ON FORM 10-K, INCLUDING
THE INFORMATION SET FORTH IN PART I, ITEM 1 -- BUSINESS, MANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS AND ELSEWHERE IN
THIS REPORT CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION
27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. ACTUAL RESULTS MAY VARY SUBSTANTIALLY FROM
THESE FORWARD-LOOKING STATEMENTS FOR MANY REASONS, INCLUDING BUT NOT LIMITED TO
THOSE SET FORTH IN "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULT OF OPERATIONS -- RISK FACTORS". ADDITIONAL INFORMATION IS AVAILABLE
IN THE COMPANY'S REPORTS AND OTHER DOCUMENTS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.
ITEM 1. BUSINESS
VitalCom (the "Company") solutions provide information that help large
healthcare organizations improve care quality and more efficiently manage the
care process, helping to reduce care-related expenditures. The Company's
solution includes an advanced technical infrastructure based upon three
fundamentals: (1) Collection of time critical patient information through an
open, wireless network (2) Data analysis using sophisticated software to reduce
false alarms, provide a common look/feel and patient history analysis and (3)
Real-time data distribution using LAN, WAN and Internet technologies. In
addition to creating the technical infrastructure, VitalCom uses information
gathered from a clinical assessment process to recommend care process changes
that optimize the value of the technology and help to standardize monitoring
quality across the health system, improve the flow of critical patient
information to care providers, speeding up the decision making process, and
manage patient flow problems including bottlenecks and transfers, helping to
improve care satisfaction, and reduce costs.
The Company's solution, called PatientNet(TM), collects patient monitoring
or life support data from the Company's proprietary ECG monitors and other
manufacturers' bedside devices, sending the data over a RF network to a mission
control-style central surveillance room. Trained technicians manning the mission
control central surveillance room evaluate information acquired from ambulatory
and point-of-care monitors for 48 to 56 patients each. In the case of a patient
emergency or other significant event, technicians use an integrated paging
system to immediately contact the appropriate caregiver. Because the networks
continuously distribute real-time patient information to patient viewers located
throughout the healthcare enterprise, caregivers have immediate access to a
patient's status. The Company believes that its PatientNet system enables
hospitals to shorten patient stays in costly intensive care units, increase
medical staff productivity, reduce costly patient transfers and improve facility
utilization. Since its introduction in 1991, the Company's enterprise-wide
monitoring systems have been installed in more than 100 acute care facilities,
with the largest network providing central surveillance of up to 300 patients
located in multiple buildings. The Company's direct sales force sells the
PatientNet system to large acute care hospitals and integrated health delivery
networks ("IHDNs").
The Company's Original Equipment Manufacturer ("OEM") channel sells central
monitoring systems as well as individual components for use in equipment
manufacturers' and/or integrators' monitoring products. OEM products offered by
the Company acquire data from the Company's ambulatory ECG monitor and from the
OEM customer's bedside monitoring devices or life support equipment. The central
monitoring system and display software for each OEM customer is developed
specifically to meet the specifications of a client.
INDUSTRY BACKGROUND
Market-driven and governmental reform initiatives have produced significant
pressures on healthcare providers to control costs, resulting in managed care
and provider capitation arrangements that shift the economic risk of healthcare
delivery from payors to providers. In order to manage this risk, healthcare
providers are changing the way in which they operate and are increasingly
focusing on controlling the cost of delivering care.
These cost control pressures are forcing hospitals to find ways to deliver
care with fewer resources. Additionally, as an increasing number of patients
receive care in lower-cost, outpatient settings the overall acuity level of
patients remaining in the hospital increases. Consequently, acute care hospitals
and IHDNs are faced with delivering quality care to more acutely ill patients
using fewer resources. In response, hospitals are increasingly turning to
technological innovation for assistance.
Historically, specific technological solutions have included patient bedside
monitors and life support equipment to assist in caring for acutely ill
patients. In high-acuity departments such as intensive care units ("ICUs"),
coronary care units ("CCUs") or "step-down" units, this equipment is typically
hard-wired to a central monitoring station. This departmental approach can be
very costly to establish and maintain, and creates a reliance on a single
vendor's monitoring hardware. In addition, dedicating equipment to individual
departments necessitates that patients be transferred in and out of the
monitored beds that are available, creating additional transfer costs and
disrupting the continuity of patient care. Lastly, the departmental approach
completely bypasses the opportunity for enterprise wide resource sharing and
consolidation.
3
4
Outside of these specialty departments, remote bedside equipment is used to
monitor and support patients. In this setting, a patient's physiologic
information is only available at the patient bedside, rather than where that
information can be readily available to caregivers. Additionally, caregivers in
these areas are subject to high patient/caregiver ratios, have limited time to
observe patient monitors and are often required to respond to false alarms that
result in the unproductive and costly use of the medical staff's time. The
Company believes that these existing patient monitoring solutions do not
sufficiently address the needs of hospitals to manage their increasing patient
acuity in a cost-effective manner.
THE VITALCOM SOLUTION
The Company's PatientNet system enables large acute care hospitals and IHDNs
to respond to cost control pressures in the healthcare industry by reengineering
labor-intensive care delivery processes to reduce costs and to raise care
quality levels with enterprise-wide monitoring care standards. Principal
benefits of the Company's solution include:
o reducing patient stays in costly ICU and CCU departments through central
surveillance of patients in less labor-intensive settings.
o increasing productivity of medical staff through the use of technicians
located in a centralized monitoring room. Technicians are trained to
monitor up to 48 to 56 patients each and notify caregivers when patients
experience a medically significant event, through standard paging
technology.
o standardizing quality across the health system by having all patients
monitored 24 x 7 by trained technicians in the mission control-style
monitoring room.
o distributing patient physiologic information to patient viewing stations
throughout the facility for convenient and immediate access by
caregivers.
o reducing costly patient transfers and improving overall facility
utilization by allowing flexible bed configurations using wireless
technology.
o improving asset utilization with the Company's wireless
OpenNet(R)application interfacing to third-party products through
programmable interfaces. The Company's OpenNet application includes
interfaces with monitoring devices from Agilent ("Agilent" formerly
Hewlett Packard, Inc.), Protocol Systems, Inc., ("Protocol") Datascope
Corporation ("Datascope") and Critikon Inc. ("Critikon") and life
support equipment from the Nellcor Puritan Bennett division of
Mallincrodt Inc. ("Mallincrodt").
o facilitating the implementation of telemedicine with the Company's
SiteLink(TM) application which allows a tertiary hospital to link its
PatientNet system to remote facilities located even hundreds of miles
away.
PRODUCTS
Enterprise-wide Monitoring Solutions
The Company's PatientNet system provides the basic infrastructure for
current and future product offerings. In 1991, the Company introduced its
computer network for ECG data providing acquisition, interpretation and
distribution of patient ECG information. The OpenNet application introduced in
the first half of 1996 expanded the Company's network capability to
multi-parameter applications by wirelessly collecting patient information from
other manufacturers' patient monitoring and life support equipment. In November
1997, the Company introduced its SiteLink application, which allows a tertiary
hospital to link its PatientNet system to one at a remote facility via
fractional T-1 lines or other common wide area network infrastructures.
Introduced in 1999, the Company's PatientNet system utilizes the following
key components: RF technology; personal computer-based central station and
proprietary display software; proprietary clinical analysis software and a
proprietary network including real-time remote display and paging. The Company's
RF technology collects patient physiologic data from the Company's proprietary
ECG ambulatory transmitters and other manufacturers' multi-parameter bedside
monitoring equipment and other manufacturers' life support equipment and
transmits that data in real-time to the mission control-style monitoring room
for interpretation and distribution. A central surveillance station consists of
multiple, networked personal computers and color monitors. The central
surveillance station is capable of simultaneously displaying up to several
hundred patients' physiologic data. One trained technician is capable of
monitoring up to six or seven personal computers, each of which receives,
interprets and displays real-time physiologic patient data, alarm settings and
equipment status for up to eight patients using the Company's proprietary
software. In the event that the Company's proprietary software detects a
medically significant event; it responds with an audio or visual alarm and
prompts the technician to
4
5
issue a pager call to the responsible caregiver. The Company's proprietary
software also stores up to 24 hours of real-time physiologic patient information
for subsequent review.
The Company's PatientNet system provides for the simultaneous distribution
of real-time physiologic patient information to multiple remote color
touch-screen displays (patient viewing stations) located throughout the
enterprise by employing proprietary real-time distribution software and
industry-standard Ethernet protocols. Patient viewing stations are located
throughout the enterprise, allowing caregivers to view patient physiologic data,
alarm settings and equipment status for any patient connected to the network
from any remote site.
ECG Applications. The Company's PatientNet system interprets and distributes
patient information acquired from an ambulatory digital telemetry transmitter,
approximately the size of a television remote control, that collects the
information through sensors attached to the patient's chest. The Company's
proprietary analysis software displays patient ECG information, including
heartrate and waveform, alarm settings and equipment status for interpretation
by a trained technician. In addition, the Company's proprietary clinical
analysis software includes algorithms to analyze patient cardiac arrhythmias,
such as asystole and ventricular fibrillation. The most recent version of the
Company's analysis software received FDA clearance in January 1995.
Multi-Parameter OpenNet Applications. The Company's OpenNet application uses
programmable interfaces and wireless technology to acquire, interpret and
distribute multi-parameter physiologic patient information, such as blood/oxygen
saturation, respiration, temperature, end-tidal CO2 and blood pressure from
patient monitoring and life support equipment of other vendors. The software and
wireless component of the OpenNet technology have been available since March
1996. The Company's OpenNet application includes interfaces with bedside
monitoring devices from Agilent (Hewlett Packard), GE Marquette Medical Systems,
Inc., Protocol, Datascope and Critikon. In November 1997 the Company received
its 510(k) clearance for additional OpenNet connections to other bedside
monitors and to ventilators. The ventilator feature allows clinicians to
receive, display, interpret, distribute and archive respiratory data of
ventilated patients, with the first interface to Mallincrodt's Series 7200
Ventilator.
SiteLink(R) Application. The Company's SiteLink application allows a
tertiary hospital to link its PatientNet system to a remote facility, even
hundreds of miles away, in real time, using standard wide-area networking
technology. Monitoring technicians at the tertiary facility provide 24-hour
surveillance for the their own site in addition to surveillance at the remote
site. The tertiary facility pages caregivers if a patient at the remote facility
is in distress and then can also provide clinical consultations (telemedicine)
to caregivers at the remote site. Physicians can receive access to their
patients from either location. The Company received FDA clearance in November
1997 for its SiteLink application, which currently is installed and running in
five different locations.
NetServer Interconnectivity Application. In 1998 the Company placed into
Market Acceptance Testing (MAT) its first connection to the clinical patient
record database of a healthcare information system. A healthcare information
system is comprised of centralized and departmental systems for financial,
practice, resource, enterprise and clinical management that includes a
repository for patient history. The Company's PatientNet system obtains admit
and discharge information, such as name and patient identification number, from
the healthcare information system and also transfers clinical patient
information in numeric form from its own ECG transmitters and other
manufacturers' monitoring and ventilator equipment to the healthcare information
system.
OEM Products
The Company's OEM products are sold on a private-label basis to equipment
manufacturers and integrators, all of which manufacture patient monitoring or
medical devices and have multi-year working relationships with the Company. The
Company's OEM products are typically used in the emergency room, post-surgical,
cardiac rehabilitation and other discrete care units within a hospital. These
departmental products are custom programmed to provide specialized analysis or
display formats required by a particular department specialty and to allow
equipment manufacturers and integrators to deliver a product that satisfies the
patient monitoring and reporting requirements of their customers. The OEM
products use many of the same components that are used in the Company's
Enterprise-wide monitoring systems, allowing for economies of scale in
development, manufacturing and inventory management. When the Company's OEM
customers offer networks, they are typically smaller in size than the
Enterprise-wide monitoring system networks sold by the Company's direct sales
force.
The OEM products include central workstations, proprietary analysis
software, RF products and network solutions, but currently they do not include
the ability to accept multiparameter information from other vendors' systems.
During 1998, the Company expanded its product offering to one OEM customer to
include the hardware and software capable of real-time distribution on an
enterprise-wide basis. This OEM can sell the redistribution capability in the
small (under 200 beds) hospital market. In addition, the Company believes that
its work with OEM customers helps it better understand the clinical procedures
and technical protocols used to create the OpenNet connections with its OEM
customers and other vendors.
5
6
CUSTOMERS
The Company sells its PatientNet system to large acute care hospitals and
IHDNs throughout the United States through its direct sales force. The Company
estimates that its potential customer base includes more than 5,200 acute care
hospitals in the United States. As of December 31, 1999, the Company had direct
sale installations of its enterprise-wide monitoring systems in more than 100
such hospitals and IHDNs. In addition, the Company sells its OEM products to
leading patient monitoring device companies. In 1998, Quinton and Datascope
accounted for approximately 19.7 % and 22.6%, respectively, of the Company's
total revenues and in 1999 Quinton and Datascope accounted for approximately
24.0% and 34.0%, respectively, of the Company's total revenues. The loss of or a
significant reduction in sales to any such customer would have a material
adverse effect on the Company's business, operating results and financial
condition.
SALES AND MARKETING
The Company sells its PatientNet system to large acute care hospitals and
IHDNs through its direct sales force. The Company's sales force is organized by
region and targets key hospitals and IHDNs within each region. The sales cycle
for enterprise-wide monitoring systems has typically been nine to 18 months from
initial contact to receipt of a purchase order and generally involves multiple
sales calls on hospital purchasing, information technology, administrative and
clinical personnel, product demonstrations at select reference sites and on-site
evaluations. The Company markets its PatientNet system through direct sales
calls, product demonstrations at select reference sites, on-site product
evaluations, participation in trade shows and advertising in trade publications.
Due to the long sales cycle and the fixed costs related to direct sales
expenses, a failure of such direct sales efforts to create an offsetting
increase in revenues and earnings would have a material adverse effect on the
Company's business, operating results and financial condition. In addition,
during the Company's long sales cycle for Enterprise-wide monitoring systems, it
may expend substantial time, effort and funds preparing a contract proposal or
negotiating a purchase order without any guarantee that it will complete the
transaction. Significant or ongoing failure to reach definitive agreements with
direct sales customers, which the Company has experienced in the past, would
have a material adverse effect on the Company's business, operating results and
financial condition. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations -- General".
The Company sells its OEM products to leading patient monitoring device
companies, many of whom have had long-term working relationships with the
Company. The Company's OEM sales team has significant experience in the
healthcare industry. The Company markets its OEM products to its customers
through expansion of existing product offerings, sales calls and participation
in trade shows.
CUSTOMER SUPPORT
The Company provides a wide range of support services to purchasers of its
PatientNet system. The Company's support program includes pre-installation
assistance in network design and planning; a training and maintenance program
for clinical and other hospital staff prior to installation and follow-up
on-site training after installation; 24-hour telephone technical support and a
consignment program during the product warranty period for systems of 24
channels or more providing for the consignment of one central station, including
one spare transmitter per eight beds. The Company provides a one-year warranty
on the equipment and software components of its PatientNet system. The Company
will repair or replace at no charge any device or software which it finds to be
defective during the warranty period. The Company offers post warranty support
programs for an annual fee including extended hardware warranty, software
maintenance and hardware and software maintenance and upgrade programs.
TECHNOLOGY
The Company believes that it has developed expertise in the following core
technologies: R.F. communication products, real-time application software,
clinical software algorithms and networking software. The Company benefits from
the expertise of its research and development staff and its investment in these
core technologies. These core technologies allow the Company's networks to
acquire, interpret and distribute physiologic patient information throughout the
facility in real-time. The term "real-time" refers to the ability to deliver
data with minimal latency on a deterministic basis. "Latency" refers to the
interval of time between the actual event and the arrival of the data.
"Deterministic" refers to the ability to accurately predict the period of
latency. Patient physiologic information is typically shown on remote displays
less than one-half second after the actual event.
Radio Frequency Communication Products. The Company's proprietary radio
frequency communication products transmit real-time physiologic information from
the patient to the central surveillance station. These communication products
operate in three radio bands: VHF (174MHz to 216 MHz, shared with TV channels
7-13); UHF (450 MHz to 470 MHz shared with land mobile users) and the 900 MHz
radio band (902 MHz to 928 MHz licensed for spread spectrum operations). The
Company has developed over-sampling, interleaving and digital packet algorithms
providing a deterministic method for reliable radio frequency transmissions. See
"Management's Discussion and Analysis of Financial Condition and Results of
Operations - Risk Factors".
6
7
Real-time Application Software. The Company has a substantial investment in
real-time application software. This includes modules for displaying physiologic
patient information such as real-time patient wave forms, the continuous storage
of patient information, trending of physiologic parameters, event storage and
reporting, a pager interface and alarm handling. This software enables the
display of physiologic data at the central station as well as on standard
desktop computer resources connected to a hospital's Intranet or connected to a
webserver via Internet.
Clinical Software Algorithms. The Company has invested substantial energy in
developing clinical analysis software to evaluate ECG information received from
the Company's transmitter and other patient monitors to report clinically
significant events. The heart beat detector uses three types of sophisticated
analysis techniques to differentiate the patient's heart beat from various
sources of noise. These include linear digital filtering, nonlinear transforms
and decision rule algorithms. These algorithms detect and classify each heart
beat for every patient on the system and detect cardiac arrhythmia events such
as asystole or ventricular fibrillation. The Company's clinical software has
received all required FDA approvals.
Real-time Networking Software. The Company has invested in developing
proprietary network algorithms that enable simultaneous viewing of real-time
physiologic patient information on multiple remote viewing stations. These
algorithms provide a deterministic method of handling network data collisions as
well as providing the minimal latency required for real-time physiologic patient
information. The Company's implementation allows for the use of industry
standard network interface controllers, hubs and routers.
PRODUCT DEVELOPMENT
The Company's research and development strategy is to focus on expanding the
capabilities of existing products and developing new products. The Company
introduced its first OpenNet applications in 1996, permitting information from
other manufacturers' multi-parameter patient monitoring to be displayed and
distributed on the Company's Enterprise-wide monitoring system. Interfaces with
bedside monitoring devices from Protocol, Datascope and Critikon, were
introduced in 1996. The Company intends to continue to expand its OpenNet
applications with interfaces to additional patient monitoring devices, many of
which require no additional FDA clearance. In November 1997 the Company received
its 510(k) clearance for additional OpenNet connectors to bedside monitors not
covered in a previous 510(k) clearance and connections to ventilators. The
ventilator connection allows clinicians to receive, display, interpret,
distribute and archive respiratory data of ventilated patients. The first
ventilator interface is to Mallincrodt's Series 7200 Ventilator. The Company
received FDA clearance in November 1997 for a product application, SiteLink(TM),
which enables the Company's Enterprise-wide monitoring systems at a tertiary
hospital to be linked to remote facilities, even hundreds of miles away, in
real-time, via a dedicated T-1 phone line. Monitoring technicians at the
tertiary hospital provide 24-hour surveillance to the remote site, paging
caregivers if a patient at the remote facility is in distress. During 1998, the
Company placed into MAT its first connection between the Company's
Enterprise-wide network and a hospital's clinical patient record software. The
Company intends to make additional connections between its Enterprise-wide
monitoring network and other HCIS products and computerized patient records.
The Company continues to evaluate emerging technologies in the
communications industry for possible use in its products. In addition, the
Company continually evaluates trends in the healthcare industry and, based on
its perceptions of market requirements, may outsource development of selected
products or technologies or may accelerate development of certain products while
deferring or canceling development of others. The completion of the development
of new or enhanced products will involve significant expenditures without
knowing whether such products will achieve the intended benefits of cost
reductions and productivity gains or whether such products will receive market
acceptance.
For the years ended December 31, 1999, 1998 and 1997, total research and
development expenditures were approximately $5.7 million, $4.7 million and $4.8
million, respectively, and represented 35.2%, 22.5% and 22.1% of revenues,
respectively. The Company expects to continue to allocate significant resources
to these efforts. There can be no assurance, however, that such research and
development efforts will be successful. Any failure of the Company's OpenNet
technology or other products under development, including other HCIS
connectivity products, to achieve their intended benefits or market acceptance
would have a material adverse effect on the Company's business, operating
results and financial condition.
BACKLOG
The Company's backlog as of December 31, 1999, 1998 and 1997 was $3.4
million, $1.1 million and $2.9 million, respectively. Backlog consists of
purchase orders for products deliverable within twelve months and primarily
represents orders from OEM customers. Purchase orders from the Company's OEM
customers are generally cancelable at any time without penalty. The Company's
backlog is not large enough to assure that its revenue targets for a particular
quarter will be met. Therefore, the Company does not consider backlog to be a
significant indication of future performance, and sales in any quarter are
dependent on orders booked and shipped during that quarter and are not
predictable with any degree of certainty.
7
8
MANUFACTURING
The Company's manufacturing operations consist primarily of final assembly
and test and quality control of materials, components, subassemblies and
systems. The Company relies on subcontractors for printed circuit board and
component assembly. The Company obtained and maintains ISO 9001/EN 29001
certification and is required to operate under the Quality System Regulation
(previously called the Good Manufacturing Practices) of the Food and Drug
Administration ("FDA"). Some of the Company's products utilize components
available in the short term from only a single or limited number of sources.
Certain of these components, such as some devices manufactured by Intel,
Burr-Brown Corporation, Motorola Semiconductor Products, Inc. and Maxim
Integrated Products, Inc., have been available only on an allocation basis in
the past and could be in scarce supply again in the future. In addition, from
time to time, certain components, subassemblies and systems used by the Company
are discontinued by manufacturers, requiring the Company to replace the
component, subassembly or system with an equivalent product or if no such
equivalent can be identified to modify and re-validate the product design. While
such allocation restrictions and discontinuances have not had a significant
adverse effect on the Company to date, any inability to obtain such components
on a timely basis or at commercially reasonable prices or to redesign the
product in a timely manner could have a material adverse effect on the Company's
business, operating results and financial condition until alternative sources
could be developed or design and manufacturing changes could be completed. The
Company does not have long-term supply agreements with its component suppliers
or subcontractors. The Company's manufacturing facility is located at its
headquarters in Tustin, California.
INTELLECTUAL PROPERTY
The Company relies on a combination of copyright, trade secret and trademark
laws, confidentiality procedures and contractual provisions to protect its
proprietary rights. The Company seeks to protect its software, circuitry
documentation and other written materials under trade secret and copyright laws,
which afford only limited protection. The Company has one patent on certain
aspects of the transmitter technology used in its products. OpenNet, SiteLink,
PatientNet, and VitalCom are trademarks of the Company. The Company cannot
assure that any of its proprietary products or technologies can be patented,
that any issued patent will provide the Company with any competitive advantages
or will not be challenged by third parties, or that the patents of others will
not have an adverse effect on the Company's ability to do business. Certain of
the Company's OEM products include 900 MHz transmission technology licensed
pursuant to a fully paid, five-year agreement expiring January 1, 2001 with a
third-party. Despite the Company's efforts to protect its proprietary rights,
unauthorized parties might attempt to copy aspects of the Company's products or
to obtain and use information that the Company regards as proprietary.
Restricting unauthorized use of the Company's products is difficult, and
although the Company is unable to determine the extent to which unauthorized
copying of its software products exists, such copying could be a potential
problem. The Company believes, however, that it leads its competitors in certain
technological developments, and that this lead affords it protection due in part
to regulatory requirements related to technological advances. Nevertheless, the
Company cannot assure that its protective measures for proprietary rights will
be adequate or that the Company's competitors will not independently develop
similar or superior technology, duplicate the Company's products or otherwise
circumvent its intellectual property rights.
COMPETITION
The Company's Enterprise-wide monitoring systems compete with systems
offered by a number of competitors, including Agilent (formerly part of the
Hewlett-Packard Company), SpaceLabs, Inc., GE Marquette Medical Systems, Inc.
and Protocol, substantially all of which have significantly greater financial,
technical, research and development and marketing resources than the Company. In
addition, many of these competitors have long-standing relationships with acute
care hospitals and IHDNs. Furthermore, consolidation in the healthcare industry
and the emergence of IHDNs has resulted in larger healthcare providers that
consolidate their purchasing with a small number of preferred vendors with whom
they have had long-standing relationships. There can be no assurance that the
Company will be able to sell to such hospitals or IHDNs or that the Company will
be able to compete successfully with such vendors, and any inability to do so
would have a material adverse effect on the Company's business, operating
results and financial condition.
The Company's OpenNet connections may face competition in the future from
patient monitoring companies, life support device companies and general purpose
data network providers. Such potential competitors may elect to enter this
market and compete with the Company using significantly greater financial,
technical, research and development and marketing resources than are available
to the Company. In addition, the Company's success in selling its
multi-parameter OpenNet connections to hospitals and IHDNs will depend to a
large extent on its ability to interface with patient monitoring and life
support devices of other vendors. Any action on the part of such other vendors
to make such interfacing more difficult or impossible could have a material
adverse effect on the Company's business, operating results and financial
condition.
The market for the Company's OEM products is also intensely competitive. The
Company's OEM customers are patient monitoring and life support device
companies, many of which have significantly greater financial, technical,
research and development and marketing resources than the Company. There can be
no assurance that current OEM customers will not elect to design and manufacture
patient monitoring and system components currently supplied by the Company or
elect to contract with other
8
9
OEM suppliers. Any such election by one or more of such companies would have a
material adverse effect on the Company's business, operating results and
financial condition.
In addition, the Company may in the future elect to incorporate in its OEM
products the hardware and software for larger networks and expand the number of
OEM customers with the hardware and software required for real-time
redistribution of information to Remote Viewing Stations for use in specialty
departments of hospitals for which the Company's OEM customers design and sell
their products. Although the Company believes that its OEM customers would not
compete with its Enterprise-wide monitoring systems because the Enterprise-wide
monitoring systems are sold to hospitals and IHDNs who elect to install larger,
more dispersed systems, the Company could face competition with its OEM
customers to the extent hospitals forego purchasing the Company's facility-wide
Enterprise-wide monitoring systems for the smaller departmental systems of its
OEM customers.
The Company believes that the principal competitive factors in its markets
are system features, product reliability, customer service and support, FDA
regulatory compliance expertise, existing relationships with hospitals and
IHDNs, company reputation, price and effectiveness of sales and marketing
efforts. In addition, the Company believes that the ability to identify the
evolving needs of the healthcare industry and the ability to develop innovative
products to meet such needs, are important competitive factors. The Company
believes that it competes favorably with respect to these factors but there can
be no assurance that the Company will continue to compete favorably.
GOVERNMENT REGULATION
Certain of the Company's products are regulated in the United States as
medical devices by the FDA under the Federal Food, Drug, and Cosmetic Act ("FDC
Act") and require implementing regulations and premarket notification clearance
or approval by the FDA prior to commercialization. In addition, certain material
changes or modifications to the intended use, labeling or manufacturing of
cleared or approved medical devices are also subject to FDA clearance or
approval. Pursuant to the FDC Act, the FDA regulates the development, testing,
safety, labeling, storage, record keeping, advertising, production and
distribution of medical devices in the United States. Noncompliance with
applicable requirements can result in civil or criminal penalties, recall or
seizure of products, or total or partial suspension of production.
Generally, before a new medical device can be introduced into the market in
the United States, the manufacturer or distributor must obtain FDA clearance by
filing a 510(k) premarket notification or obtaining approval of a premarket
approval ("PMA") application. If a medical device manufacturer or distributor
can establish that a device is "substantially equivalent" to a legally marketed
device for which the FDA has not called for PMA's, the manufacturer or
distributor may seek clearance from the FDA to market the device by filing a
510(k) premarket notification. The 510(k) premarket notification may need to be
supported by appropriate data establishing the claim of substantial equivalence
to the satisfaction of the FDA.
If a manufacturer or distributor of a medical device cannot establish
substantial equivalence, the proposed device must be approved through a PMA
application, which must be supported by statistical analysis of clinical data.
The PMA application approval process can be expensive, uncertain and lengthy. To
date the Company has received clearance on all of its products under the 510(k)
process and has not been required to file a PMA application. The FDA has
published a proposed rule that would require over forty devices, including those
using arrhythmia software produced by the Company and its competitors, following
a notice period, to receive PMA approvals or be discontinued for sale. A
petition has been filed by some industry participants, including the Company, in
response to the notice, to formally request that the FDA reclassify arrhythmia
software devices from Class III devices to Class II devices. This petition is
currently under FDA review. If the FDA reclassifies arrhythmia software devices
to Class II, the Company's products will not require any additional clearances
if a PMA application is not filed and approved within a specified time frame.
However, if the FDA does not reclassify the arrhythmia software devices and
publishes its final rule, such software devices would be subject to the lengthy
and expensive PMA process, which could interrupt or terminate the sales of the
Company's or its competitors' arrhythmia software devices. Any such interruption
or termination could have a material adverse effect on the Company's business,
financial condition and results of operations. The Company is required to adhere
to applicable FDA regulations including the new Quality System Regulation, Title
21, part 820, (previously called the Good Manufacturing Practices), which
include testing, control, and documentation requirements and the Medical Device
Reporting Regulation. Failure to receive or delays in receipt of FDA clearance
or approvals, including the need for extensive clinical trials or additional
data as a prerequisite to clearance or approval, would have a material adverse
effect on the Company's business, operating results and financial condition.
Changes in existing regulations or adoption of new governmental regulations or
policies could prevent or delay required regulatory approvals of the Company's
products.
The Company's RF transmitter devices are subject to regulation by the
Federal Communication Commission ("FCC"), and applicable approvals must be
obtained before shipment of such products. The Company believes that all of its
products designated for sale in the United States meet applicable Federal
Communications Commission (FCC) regulations, including US FCC Part 15 for
electromagnetic emissions. The FCC approval process starts with the collection
of test data that demonstrates that a product meets the requirements stated in
Part 15 of the FCC regulations. This data is then included as part of a report
and application that is submitted to
9
10
the FCC requesting approval. The FCC may grant or request additional information
or withhold approval. Any failure of the Company's products to conform to
governmental regulations or any delay or failure to obtain required FCC
approvals in the future, if any, could cause the delay or loss of sales of the
Company's products and therefore have a material adverse effect on the Company's
business, financial condition and result of operations.
The Company's proprietary communication products transmit real-time
physiologic information from the patient to the central surveillance station.
These communication products currently operate in three radio bands: VHF (174
MHz to 216 MHz, shared with TV channels 7-13); UHF (450 MHz to 470 MHz, shared
with land mobile users); and the 900 MHz radio band (902 MHz to 928 MHz licensed
for Spread Spectrum operation). The majority of the Company's RF products use
the vacant television frequencies in the VHF band. The FCC is requiring all
television stations to implement digital broadcasting transmission for High
Definition Television (HDTV). Some major metropolitan areas were required to
implement HDTV by December 31, 1998 and other markets will be required to
implement by December 31, 2006. In order to implement HDTV the FCC has granted
each TV channel an additional 6 MHz channel for digital broadcasting until the
transition period ends, at which time the broadcaster would return one of the
two channels. As TV stations use the additional 6 MHz channel for the digital
broadcasting transition, which may take years, they may overlap into the radio
spectrum which has been used for medical RF applications. Customers of the
Company's lower power RF communication products may begin seeing more
interference in the future. This interference may result in the Company's
hospital biomedical personnel having to re-tune the Company's RF transmitters to
other channels in order to reduce interference. In the event of high
interference the Company's customers may need to purchase equipment to transmit
in the UHF frequency range. In 1998 the FCC expanded the usable UHF frequencies
for medical RF from the licensed 450 MHz to 470 MHz band to the previously
unlicensed 470 MHz to 668 MHz frequency range. With VHF frequency ranges
available for medical RF use potentially becoming more limited and the UHF
frequency ranges expanding, the Company's competitors who have historically
focused their RF products in what was the more limited UHF band, may now have a
competitive advantage as compared to the Company, until such time as the Company
expands its UHF RF product offerings. Any such competitive advantage of the
Company's competitors and any additional development costs associated with
expanding the Company's UHF RF product offerings could have a material adverse
effect on the Company's business, operating results and financial condition.
Additionally, future regulatory changes could significantly affect the Company's
operations by diverting the Company's development efforts, making current
products obsolete or increasing the opportunity for additional competition which
could have a material adverse effect on the Company's business, operating
results and financial condition.
During 1998 the Company joined a task force created by the American Hospital
Association (AHA) and the FDA called the Medical Telemetry Task Force (the "Task
Force") along with other medical RF users, organizations, and vendors, including
its competitors. The purpose of the Task Force was to respond to potential
interference problems from HDTV, land mobile users and low power television to
wireless patient monitoring devices by recommending both rule making language
and specific spectrum allocation to the FCC. The Task Force's mission was to
identify protected spectrum candidates for future medical telemetry use,
evaluate use and make recommendations to the FCC. As such the Task Force
petitioned the FCC to allocate the UHF 608 MHz to 614 MHz band, currently
reserved for radio astronomy, for medical use on a primary basis. The Task Force
submitted its recommendations to the FCC which then filed a Notice of Proposed
Rule Making (NPRM, FCC docket # 99-182). Once the FCC approves the rulemaking,
which the Company believes is probable, the Company may be at a disadvantage in
the marketplace if one or some of its competitors develop and introduce RF
products in this new band before the Company introduces products in the new
band, resulting in lost or delayed revenues. In addition, the costs of
developing RF transmitter and receiver products is expensive and is diverting
research and development resources from other projects resulting in higher costs
and delayed projects. Any such competitive advantage of the Company's
competitors and any additional development costs associated with expanding the
Company's UHF RF product offerings could have a material adverse effect on the
Company's business, operating results and financial condition. Additionally,
future regulatory changes could significantly affect the Company's operations by
diverting the Company's development efforts, making current products obsolete or
increasing the opportunity for additional competition which could have a
material adverse effect on the Company's business, operating results and
financial condition.
If the Company were to attempt to market its products and components in
Europe and certain other foreign jurisdictions, the Company and its distributors
and agents would have to obtain required regulatory approvals and clearances and
otherwise comply with extensive regulations regarding safety and manufacturing
processes and quality. These regulations, including the requirements for
approvals or clearance to market and the time required for regulatory review
vary from country to country.
EMPLOYEES
As of December 31, 1999, the Company had approximately 136 full-time
employees, of which 31 were in customer service, marketing and sales, 34 were in
research and development, 54 were in manufacturing, quality assurance and
regulatory affairs and 17 were in administration. None of the Company's
employees is covered by a collective bargaining agreement, the Company has
experienced no work stoppages and VitalCom believes that its relationship with
its employees is good.
10
11
ITEM 2. PROPERTIES
The Company occupies approximately 46,000 square feet of space at its
headquarters in Tustin, California under a lease expiring in June 2005, with an
option to extend through June 2010. The Company believes that this facility will
be adequate to satisfy its anticipated business requirements.
ITEM 3. LEGAL PROCEEDINGS
The Company is not a party to any material legal proceedings.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters have been submitted to a vote of the Company's shareholders
since the Company's last annual meeting of shareholders in May 1999.
11
12
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Market and Market Price for Common Stock. VitalCom Inc. common stock,
$0.0001 par value per share, is traded over the counter under the symbol "VCOM"
and is an authorized security for quotation on the Nasdaq Small Cap Market
("Nasdaq/SC"). In September 1999, the Company no longer met all of the
requirements for trading on the Nasdaq National Market, and was required to be
traded on the Nasdaq/SC. There was no interruption in the trading of the
Company's stock due to the change in market listing, and the Company currently
meets all the listing requirements of the Nasdaq/SC.
The market prices of a share of VitalCom Inc. common stock are set forth
below. The prices reflect the high and low trading prices for each quarter and
the year ended December 31, 1999, since the Company's initial public offering in
February 1996, as reported by Nasdaq.
Three Months Ended Year Ended Year Ended Year Ended Year Ended
---------------------------------------------- December 31, December 31, December 31, December 31,
March 31 June 30 September 30 December 31 1996 1997 1998 1999
-------- ------- ------------ ----------- ------------ ------------ ------------ ------------
1996
High.................. $20.000 $23.250 $16.813 $6.000 $23.250
Low................... 12.625 12.875 4.375 5.125 4.375
1997
High ................. 5.750 5.625 5.063 5.563 $5.750
Low................... 4.375 4.500 4.000 3.875 3.875
1998
High ................. 5.000 4.500 4.000 3.063 $5.000
Low................... 4.063 3.000 2.375 1.500 1.500
1999
High.................. 3.000 2.250 2.375 3.500 $3.500
Low................... 1.156 1.063 1.750 0.750 0.750
Holders. The approximate number of holders of record of VitalCom Inc. common
stock, as recorded on the books of VitalCom's Registrar and Transfer Agent, as
of March 15, 2000 was 37.
Dividends. VitalCom has not paid cash dividends on its common stock and does
not currently have any plans to pay such dividends in the foreseeable future.
The dividend policy of VitalCom is reviewed from time to time by the Company's
Board of Directors in light of its earnings and financial condition and such
other business considerations as the Board of Directors considers relevant.
UNREGISTERED SALES OF THE REGISTRANT'S EQUITY SECURITIES DURING LAST FISCAL YEAR
Common Stock Contributions to 401(k) Plan. At December 31, 1998 the Company
was obligated to issue 27,057 shares of Common Stock to employees as a matching
contribution to the 401(k) Plan for the fourth quarter of 1998. This stock match
was made in the first quarter of 1999.
12
13
ITEM 6. SELECTED FINANCIAL DATA
The selected financial data set forth below for the periods and the dates
indicated are derived from the audited financial statements of the Company. The
statement of operations data for each of the three fiscal years in the period
ended December 31, 1999, and the balance sheet data at December 31, 1998 and
1999, has been derived from the audited financial statements included herein
which have been audited by Deloitte & Touche LLP, independent auditors. The
Company's statements of operations data for the fiscal years ended December 31,
1995 and 1996 and balance sheet data as of December 31, 1995, 1996 and 1997,
have been derived from audited financial statements, not included herein, also
audited by Deloitte & Touche LLP, independent auditors. The data set forth below
should be read in conjunction with "Management's Discussion and Analysis of
Financial Condition and Results of Operations" and the Financial Statements and
Notes thereto included elsewhere in this report.
Year Ended December 31,
--------------------------------------------------------
1995 1996 1997 1998 1999
-------- -------- -------- -------- --------
(In thousands, except per share data)
Statements of Operations Data:
Revenues $ 23,964 $ 18,372 $ 21,794 $ 20,859 $ 16,290
-------- -------- -------- -------- --------
Cost of revenues 10,299 9,680 11,477 9,561 7,589
-------- -------- -------- -------- --------
Gross profit 13,665 8,692 10,317 11,297 8,701
-------- -------- -------- -------- --------
Operating expenses:
Sales and marketing 6,442 9,515 8,562 6,794 6,128
Research and development 2,673 5,434 4,816 4,698 5,729
General and administrative 1,644 2,507 2,536 2,159 2,358
Restructuring charges 481
-------- -------- -------- -------- --------
Total operating expenses 10,759 17,937 15,914 13,651 14,215
-------- -------- -------- -------- --------
Operating income (loss) 2,906 (9,245) (5,597) (2,353) (5,514)
-------- -------- -------- -------- --------
Other income (expense), net (130) 975 973 890 759
-------- -------- -------- -------- --------
Income (loss) before provision (benefit)
for income taxes 2,776 (8,270) (4,624) (1,463) (4,755)
Provision (benefit) for income taxes 1,193 (1,902) 26 25 36
-------- -------- -------- -------- --------
Net income (loss) $ 1,583 $ (6,368) $ (4,650) $ (1,488) $ (4,791)
======== ======== ======== ======== ========
Net income (loss) per basic common share(1) $ 0.30 $ (0.90) $ (0.58) $ (0.18) $ (0.60)
======== ======== ======== ======== ========
Net income (loss) per diluted common share(1) $ 0.28 $ (0.90) $ (0.58) $ (0.18) $ (0.60)
======== ======== ======== ======== ========
Weighted average basic common shares(1) 5,313 7,084 8,001 8,148 8,046
-------- -------- -------- -------- --------
Weighted average diluted common shares(1) 5,671 7,084 8,001 8,148 8,046
======== ======== ======== ======== ========
December 31,
--------------------------------------------------------
1995 1996 1997 1998 1999
-------- -------- -------- -------- --------
(In thousands)
Balance Sheet Data:
Cash equivalents and short-term investments $ 2,164 $ 20,120 $ 18,157 $ 15,830 $ 12,380
Working capital 6,236 23,980 19,965 19,249 14,144
Total assets 13,353 31,921 26,708 24,223 18,686
Long-term debt, excluding current portion 1,042 82 60 32
Total stockholders' equity (deficit) (2,973) 26,973 22,521 21,462 16,105
- -----------------
(1) See Note 1 of the Notes to the Financial Statements for a description of
shares used in calculating net income (loss) per share.
13
14
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
GENERAL
VitalCom Inc. provides computer networks and related radio communications
products that acquire, interpret and distribute real-time patient monitoring
information. The Company's computer and radio networks acquire physiologic data
generated by its own proprietary ECG monitors and other manufacturers' bedside
equipment located throughout a healthcare facility. The Company's products are
sold through a direct sales force to acute care hospitals and integrated
healthcare delivery networks ("IHDNs") and on an Original Equipment Manufacturer
("OEM") basis to patient monitoring equipment manufacturers.
Revenues from sales of Enterprise-wide Monitoring Systems, and the recently
introduced PatientNet Enterprise Monitoring Systems, sold by the Company's
direct sales force are recognized upon shipment. The sales cycle for
Enterprise-wide Monitoring Systems has typically been from nine to 18 months,
and the Company expects that the sales cycle for PatientNet will be of similar
length. The Company has experienced seasonal variations in sales of its
Enterprise-wide Monitoring Systems, with sales in the first quarter typically
lower than the preceding fourth quarter's sales due to customer budget cycles
and sales remaining relatively flat during the third quarter. Furthermore, a
large percentage of a particular quarter's shipments of Enterprise-wide
Monitoring Systems have historically been recorded in the last weeks of the
quarter.
Revenues from sales of OEM products are recognized upon shipment. The
selling cycle for OEM products varies depending upon product mix and the extent
to which the Company develops customized operating software for a particular OEM
customer. In addition, the Company has experienced seasonal variations in sales
of its OEM products, with sales in the first quarter typically lower than the
preceding fourth quarter's sales and third quarter sales of OEM products
generally being lower than other quarters.
The Company's products are generally shipped as orders are received and,
accordingly, the Company typically operates with limited backlog. As a result,
sales in any quarter are dependent on orders recorded and shipped in the current
quarter.
To date, the Company has not capitalized software development expenses.
However, the development of new products or the enhancement of existing products
may require capitalization of such expenses in the future. See Note 1 of the
Notes to the Financial Statements.
RESULTS OF OPERATIONS
The following table sets forth the percentage of total revenues represented
by certain statements of operations data for the periods indicated:
Year Ended December 31,
----------------------------
1997 1998 1999
------ ------ ------
Revenue 100.0% 100.0% 100.0%
Cost of revenues 52.7 45.8 46.6
----- ----- -----
Gross profit 47.3 54.2 53.4
----- ----- -----
Operating expenses:
Sales and marketing 39.3 32.6 37.6
Research and development 22.1 22.5 35.2
General and administrative 11.6 10.3 14.5
----- ----- -----
Total operating expenses 73.0 65.4 87.3
----- ----- -----
Operating loss (25.7) (11.3) (33.9)
Other income, net 4.5 4.3 4.7
----- ----- -----
Loss before provision for income taxes (21.2) (7.0) (29.2)
Provision for income taxes 0.1 0.1 0.2
----- ----- -----
Net loss (21.3)% (7.1)% (29.4)%
===== ===== =====
COMPARISON OF THE YEARS ENDED 1999, 1998 AND 1997
Total Revenues. Total revenues consist of revenue from sales of
Enterprise-wide Monitoring Systems and OEM products, together with fees for
installation and servicing of products. Total revenues decreased 21.9% to $16.3
million in 1999 from $20.9 million in 1998. Total revenues decreased 4.3% to
$20.9 million in 1998 from $21.8 million in 1997. Revenues from Enterprise-wide
Monitoring Systems sales decreased 41.4% to $5.1 million in 1999 from $8.8
million in 1998. Revenues from Enterprise-wide Monitoring Systems sales
decreased 5.0% to $8.8 million in 1998 from $9.3 million in 1997. Revenues from
OEM product sales decreased 7.7% to $11.1 million in 1999 from $12.1 million in
1998. Revenues from OEM product sales decreased 3.7% to $12.1 million in 1998
from $12.5 million in 1997. The decrease in Enterprise-wide Monitoring Systems
sales in 1999 was primarily due to
14
15
delays in the signing of sales agreements with hospitals, as hospitals diverted
their capital spending to address other vendors' Year 2000 issues. Additionally,
these delays were caused by the extended analysis of the Company's new product
offerings and after sales support programs by prospective customers. The
decrease in Enterprise-wide Monitoring Systems sales in 1998 was due to the
Company's difficulties in rebuilding its sales force and funnel of potential new
business from the 1996 direct sales business development restructuring. The
decrease in OEM product sales in 1999 resulted from a shift in sales strategy by
a large OEM customer following its sale to new investors. The decrease in OEM
product sales in 1998 reflects the reduction in sales to the Company's largest
OEM customer, due to weaker demand in their departmental monitoring market.
Gross Profit. Cost of goods sold includes material, direct labor, overhead
and, for Enterprise-wide Monitoring Systems, installation expenses. Cost of
revenues decreased 20.6% to $7.6 million from $9.6 million in 1998, on a 21.9%
decrease in revenues in 1999. Cost of revenues decreased 16.7% to $9.6 million
in 1998 from $11.5 million in 1997, on a 4.3% revenue decrease in 1998. Gross
margins were 53.4%, 54.2% and 47.3% in 1999, 1998 and 1997, respectively. The
decrease in gross margin in 1999 as compared to 1998 was due to the lower
percentage of Enterprise-wide Monitoring Systems in the sales mix, which
historically have generated higher gross margins than OEM Systems. The increase
in gross margin in 1998 as compared to 1997 was due to price decreases in
material costs for personal computer and RF board assembly materials and reduced
overhead costs for overtime, product liability insurance and warranty costs.
Sales and Marketing Expenses. Sales and marketing expenses include payroll,
commissions and related personnel costs attributable to Enterprise-wide
Monitoring Systems and OEM sales and marketing personnel, travel and
entertainment expenses, and other promotional expenses. Sales and marketing
expenses decreased 9.8%, to $6.1 million in 1999 from $6.8 million in 1998.
Sales and marketing expenses decreased 20.7%, to $6.8 million in 1998 from $8.6
million in 1997. The decrease in sales and marketing expenses in 1999 from 1998
was primarily due to lower sales personnel salaries associated with the
reduction in the number of direct sales representatives, as well as reduced
commissions and travel expenses resulting from the reduced revenue volumes in
1999. The decrease in sales and marketing expenses in 1998 from 1997 was due to
lower salaries and commission expenses associated with the reduction in sales
personnel, lower travel expenses and a reduction in marketing and promotion
costs.
Research and Development Expenses. Research and development expenses include
payroll and related costs attributable to research and development personnel,
prototyping expenses and other costs. Research and development expenses
increased 22.0% to $5.7 million in 1999 from $4.7 million in 1998. Research and
development expenses decreased 2.4% to $4.7 million in 1998 from $4.8 million in
1997. Research and development expenses increased in 1999 from 1998 due to
higher third party contractor expenses related to the Company's development of
prototype hardware products. Research and development expenses decreased in 1998
from 1997 due to lower salary expenses associated with the lower headcount in
1998.
General and Administrative Expenses. General and administrative expenses
include accounting, finance, MIS, human resources, general administration,
executive officers and professional fee expenses. General and administrative
expenses increased 9.2% to $2.4 million in 1999 from $2.2 million in 1998.
General and administrative expenses decreased 14.9% to $2.2 million in 1998 from
$2.5 million in 1997. The increase in spending in 1999 in comparison to 1998 was
primarily due to higher salaries and employee benefits expenses, as well as
increased professional fees. The decrease in spending in 1998 in comparison to
1997 was primarily due to the reduction in legal and professional fees.
Other Income, Net. Other income, net consists primarily of interest income
earned on proceeds from the Company's initial public offering, net of payments
for outstanding indebtedness. Other income, net, in 1999 decreased to $758,555
as compared to $889,621 in 1998. This decrease was due to lower income derived
from the short-term investments in comparison to the prior year. Other income,
net in 1998 decreased $83,347 to $889,621 due to lower income derived from the
Company's short-term investment portfolio.
Provision for Income Taxes. The Company paid minimal state taxes in 1999,
1998 and 1997 due to its net loss position. The Company's utilization of its
credit carryforwards depends upon future income and may be subject to an annual
limitation, required by the Internal Revenue Code of 1986 and similar state
provisions (see Note 9 of the Notes to the Financial Statements).
LIQUIDITY AND CAPITAL RESOURCES
The Company has financed its operations (including capital expenditures)
through net proceeds from the Company's February 1996 initial public offering,
cash and cash equivalent balances, a bank line of credit and long-term debt.
During the year ended December 31, 1996 the Company issued 2,300,000 shares of
common stock in its February 1996 initial public offering, raising $25.6
million, net of expenses. At December 31, 1999, the Company had $12.4 million in
cash, cash equivalents and short-term investments as compared to $15.8 million
at December 31, 1998.
The Company used $2.3 million of cash for operating activities in 1999,
compared to $2.2 million and $1.7 million in 1998 and 1999, respectively to fund
the net losses in 1999, 1998 and 1997 of $4.8 million, $1.5 million and $4.6
million, respectively. Of the net cash used in operating activities in 1999,
$390,186 was used for the increase in prepaid expenses, $241,151 was
attributable to the
15
16
reduction in the accrued warranty reserve, $113,053 was used for the increase of
inventories and $85,336 was used to pay down accrued liabilities. During 1999,
the net loss of $4.8 million and the uses of cash were partially offset by the
$2.3 million decrease in accounts receivable, the $693,027 in non-cash
adjustments provided by depreciation and amortization of fixed assets and
intangible assets, and $154,975 was attributable to the increase in accrued
payroll and related costs. Of the net cash used in operating activities in 1998,
$842,163 was used for the increase in account receivables, $620,857 was used to
pay down accrued liabilities, $393,168 was used for payroll and related costs
and $210,797 was attributable to the reduction in the accrued warranty reserve.
During 1998, uses of cash were partially offset by the $735,338 in non-cash
adjustments provided by depreciation and amortization of fixed assets and
intangible assets, $420,600 was provided by the reduction in inventories, and
$259,985 in the non-cash adjustment provided by the equity contribution to the
401(k) plan. The 1997 net loss of $4.6 million and the $1.6 million increase in
accounts receivable was partially offset by decreases in inventories and income
tax receivable of $1.4 million and $2.9 million, respectively.
The Company used $385,604 in investing activities in 1999 of which $481,780
was used for capital expenditures, compared to $347,293 in cash provided by
investing activities and $6.4 million in cash used in investing activities in
1998 and 1997, respectively. Cash used in investing activities in 1998 and 1997
was primarily for the purchase of capital expenditures and net purchases of
short-term investments.
The Company used $665,022 of cash from financing activities in 1999. In
1998 and 1997, the Company generated $144,949 and $176,691, respectively. The
primary use of cash from financing activities in 1999 was the repurchase of
363,550 shares of the Company's common stock at a total cost of $740,154. The
primary source of cash from financing activities in 1998 and 1997 was the net
proceeds of cash from the issuance of common stock and its employee stock
purchase plan in the amounts of $169,813 and $198,189, respectively.
At December 31, 1999, the Company's principal sources of liquidity
consisted of $12.4 million of cash, cash equivalents and short-term investments,
and $5.0 million of available credit facilities. During the year ended December
31, 1999, the Company had a secured lending arrangement (the "Agreement") with
Silicon Valley Bank, providing for a $5.0 million revolving line of credit. The
Agreement expired on December 31, 1999. In March 2000, the Company and the bank
entered into a letter of commitment for the renewal of the Agreement through
March 2001. At December 31, 1999, there were no borrowings outstanding under the
Agreement.
The Company's principal commitment at December 31, 1999 consisted of a lease
on its office and manufacturing facility. The Company expects to spend
approximately $1.4 million for capital expenditures, primarily equipment and
computer equipment, during 2000.
The Company believes that existing cash resources will be sufficient to
fund the Company's operations for at least the next twelve months.
YEAR 2000 COMPUTER SYSTEMS COMPLIANCE
On January 1, 2000, many companies faced a potentially serious information
technology (IT) systems problem because many software applications and
operational programs written in the past did not properly recognize calendar
dates beginning in the Year 2000. This problem could have forced computers or
machines, which utilize date dependent software to either shut down or provide
incorrect data or information. The Company, led by its Y2K Task Force, examined
its IT and Non-IT Systems to determine whether its software applications and
computer and information systems were compliant with the Year 2000. The
Company's remediation efforts for the systems found not to be Year 2000
compliant included, but were not limited to, internal upgrade efforts, vendor
provided upgrades, replacement, and decommissioning of obsolete systems and
equipment. Based on these efforts the Company considered its critical and
non-critical business systems to be Year 2000 compliant as of December 31, 1999.
At this time the Company has not experienced any material Year 2000 related
problems with its IT systems or software applications, and has not experienced
any material problems with key Company suppliers or customers related to Year
2000. There has been no material impact on the Company's business, financial
condition or results of operations related to the Year 2000.
The Company spent approximately $200,000 on external and internal costs
associated with its Year 2000 compliance efforts. These costs were funded
through the Company's cash flows from operations and did not have a material
effect on results of operations or financial condition.
The Company intends to continue to review its IT systems as well as monitor
its key suppliers and customers for any undetected Year 2000 issues which may
not yet be known. However, the Company does not currently believe that there are
any undetected Year 2000 issues that could have a material impact on the
Company's business, financial condition or results of operations.
16
17
RECENT ACCOUNTING PRONOUNCEMENTS
In June 1998, the FASB released Statement of Financial Accounting Standards
No. 133 (SFAS 133), Accounting for Derivative Instruments and Hedging
Activities. SFAS 133 establishes accounting and reporting standards for
derivative instruments, including certain derivative instruments embedded in
other contracts, and for derivatives used for hedging activities. It requires
that all derivatives be recognized either as an asset or liability, and measures
them at fair value. SFAS 133, as amended, is effective for all fiscal quarters
for fiscal years beginning after June 15, 2000. The Company believes that the
application of SFAS 133 will not have a material impact on the Company's
financial statements.
EUROPEAN MONETARY UNION
Within Europe, the European Economic and Monetary Union (the "EMU")
introduced a new currency, the euro, on January 1, 1999. The new currency is in
response to the EMU's policy of economic convergence to harmonize trade policy,
eliminate business costs associated with currency exchange and to promote the
free flow of capital, goods and services.
On January 1, 1999, the participating countries adopted the euro as their
local currency, initially available for currency trading on currency exchanges
and non-cash transactions such as banking. The existing local currencies, or
legacy currencies, will remain legal tender through January 1, 2002. Beginning
on January 1, 2002, euro-denominated bills and coins will be issued for cash
transactions. For a period of up to six months from this date, both legacy
currencies and the euro will be legal tender. On or before July 1, 2002, the
participating countries will withdraw all legacy currencies and exclusively use
the euro.
The Company's transactions are recorded in U.S. Dollars and the Company
does not currently anticipate future transactions being recorded in the euro.
Based on the lack of transactions recorded in the euro, the Company does not
believe that the euro will have a material effect on the financial position,
results of operations or cash flows of the Company. In addition, the Company has
not incurred and does not expect to incur any significant costs from the
continued implementation of the euro, including any currency risk, which could
materially affect the Company's business, financial condition or results of
operations.
The Company has not experienced any significant operational disruptions to
date and does not currently expect the continued implementation of the euro to
cause any significant operational disruptions.
RISK FACTORS
Dependence on Increased Market Acceptance of Enterprise-wide Monitoring
Systems. In 1999, sales of the Company's Enterprise-wide Monitoring Systems
decreased 41.4% to $5.1 million from $8.8 million in 1998. In 1998, sales of the
Company's Enterprise-wide Monitoring Systems decreased 5.0% to $8.8 million from
$9.3 million in 1997. In 1997, sales of the Company's Enterprise-wide Monitoring
Systems increased 12.8% to $9.3 million from $8.2 million in 1996. Since 1995,
the Company's sales levels for its Enterprise-wide Monitoring Systems has been
lower than expected, which, together with investments and expense levels that
are incurred based on the expectation of higher sales, has resulted in net
losses in each year since 1995 and have had a material adverse effect on the
Company's business, operating results and financial condition. If the Company is
not successful in increasing sales levels of its Enterprise-wide Monitoring
Systems in future periods, the Company's business, operating results and
financial condition will continue to be materially adversely affected. In
addition, although the Company's Enterprise-wide monitoring products have been
installed in more than 100 hospitals, there is no assurance that the Company's
products will achieve the hospital penetration necessary to increase sales.
Introduction of New Product - PatientNet System for the e-Hospital- and
Deferred Revenue. In July 1999 the Company announced a new product to be sold by
the Company's direct sales force - "PatientNet, an enterprise monitoring
solution for the electronic hospital". The new PatientNet System for the
e-Hospital will replace the Company's existing product line of Enterprise-wide
Monitoring products sold by its direct sales force, includes open system
architecture, enterprise-wide connectivity with web-enabled access, more
connections to other manufacturers' monitoring equipment and other additional
features and functions. In addition, it is the platform for the Company's
anticipated implementation of the new medical radio frequency (RF) bands
proposed by industry to the Federal Communications Commission (FCC). In
connection with the introduction of its new Enterprise-wide Monitoring System
for the e-Hospital the Company re-priced its products, introduced after sales
support products including software maintenance, extended hardware warranty and
hardware obsolescence programs. The Company offered after sales support
agreements and upgrades, when and if available, to its existing hospital
customers at a promotional price through December 31, 1999.
Customer Concentration; Dependence on Departmental Products. The Company's
OEM product sales, which represented approximately 53.7%, 57.9% and 68.6% of the
Company's total net revenues in 1997, 1998 and 1999, respectively, have
historically been to a small number of OEM customers. In 1997, Quinton
Instrument Company ("Quinton") and Datascope Corporation ("Datascope") accounted
for approximately 12.2% and 25.0%, respectively, of the Company's total revenues
and in 1998 Quinton and Datascope accounted for approximately 19.7% and 22.6%,
respectively, of the Company's total revenues. In 1999, Quinton and Datascope
accounted for approximately 24.0% and 34.0%, respectively. The loss of, or a
reduction in sales to, any such OEM customer would have a material adverse
effect on the Company's business, operating results and financial condition.
17
18
Fluctuations in Quarterly Results. The Company's quarterly operating results
have fluctuated in the past and may fluctuate significantly from quarter to
quarter in the future as a result of a number of factors, including, but not
limited to the size and timing of orders; the length of the sales cycle; the
Company's success in expanding its sales and marketing programs and the effects
of changes in sales force alignment; the ability of the Company's customers to
obtain budget allocations for the purchase of the Company's products; changes in
pricing policies or price reductions by the Company or its competitors; mix of
sales between Enterprise-wide Monitoring Systems and OEM products; the timing of
new product announcements and introductions by the Company or its competitors;
deferrals of customer orders in anticipation of new products or product
enhancements; the Company's ability to develop, introduce and market new
products and product enhancements; market acceptance of new products or product
enhancements; the Company's ability to control costs; the availability of
components; costs associated with responding to software "bugs" or errors;
regulatory compliance and timing of regulatory clearances; changes in government
regulations and other regulatory developments; and general economic factors.
The Company's products are generally shipped as orders are received and,
accordingly, the Company has historically operated with limited backlog. As a
result, sales in any quarter are dependent on orders booked and shipped in that
quarter and are not predictable with any degree of certainty. Further, a large
percentage of any quarter's shipments have historically been booked in the last
weeks of the quarter. In addition, a significant portion of the Company's
expenses are relatively fixed, and the amount and timing of increases in such
expenses are based in large part on the Company's expectations for future
revenues. If revenues are below expectations in any given quarter, the adverse
effect may be magnified by the Company's inability to maintain gross margins and
to decrease spending to compensate for the revenue shortfall. This dynamic has
contributed to the Company's net losses in the past. Further, the Company has
sometimes experienced seasonal variations in operating results, with sales in
the first quarter being lower than in the preceding fourth quarter's sales due
to customer budget cycles and sales remaining relatively flat during the third
quarter.
Transfer of Securities from the Nasdaq National Market to the Nasdaq
SmallCap Market and Possible Delisting of Securities from the Nasdaq Small Cap
Market. The Company's Common Stock historically traded on the Nasdaq National
Market and was moved to the Nasdaq Small Cap Market during the third quarter of
1999 as the Company did not meet one National Market continued listing
requirement that the market value of publicly held shares must be at least $5
million. The Nasdaq Small Cap Market's continued listing standards require the
Company to have (i) at least 500,000 shares publicly held; (ii) a market value
of publicly held shares of at least $1 million; (iii) net tangible assets of at
least $2 million; (iv) at least 300 shareholders of round lots; (v) at least two
market makers and (vi) a minimum bid price of at least $1 per share. If the
Company fails to comply with the listing standards, it may become delisted from
the Nasdaq Small Cap Market which could adversely affect the ability or
willingness of investors to purchase the Company's securities and therefore
would severely adversely affect the market liquidity for the Company's
securities.
Lengthy Sales Cycle. The decision by a healthcare provider to replace or
substantially upgrade its clinical information systems typically involves a
major commitment of capital and an extended review and approval process, and
this review and approval process is becoming more complex, more financially
oriented and increasingly subject to overall integration into the hospital's
information systems planning. The sales cycle for the Company's Enterprise-wide
Monitoring Systems has typically been nine to 18 months from initial contact to
receipt of a purchase order. During this period, the Company expends substantial
time, effort and funds preparing a contract proposal and negotiating a purchase
order without any guarantee that the Company will complete the transaction. Any
significant or ongoing failure to reach definitive agreements with customers has
in the past and may in the future have a material adverse effect on the
Company's business, operating results and financial condition.
Competition. The Company's Enterprise-wide Monitoring Systems compete with
systems offered by a number of competitors, including Agilent, SpaceLabs, Inc.
and GE Marquette Medical Systems, Inc., all of which have significantly greater
financial, technical, research and development and marketing resources than the
Company. In addition, many of these competitors have longstanding relationships
with acute care hospitals and IHDNs. There can be no assurance that the Company
will be able to sell to such hospitals or IHDNs or that the Company will be able
to compete successfully with such vendors, and any inability to do so could have
a material adverse effect on the Company's business, operating results and
financial condition. While the Company is not aware of any competitive open
system multi-parameter Enterprise-wide Monitoring Systems currently available,
the Company's OpenNet applications may face significant competition in the
future from HCIS providers, patient monitoring companies, life support device
companies and general purpose data network providers. Such potential competitors
may elect to enter this market and compete with the Company using significantly
greater financial, technical, research and development and marketing resources
than are available to the Company. In addition, the Company's success in selling
its multi-parameter OpenNet networks to hospitals and IHDNs will depend to a
large extent on its ability to interface with patient monitoring and life
support devices of other vendors. Any action on the part of such other vendors
to make such interfacing more difficult or impossible could have a material
adverse effect on the Company's business, operating results and financial
condition. The market for the Company's OEM products is also intensely
competitive. The Company sells to a range of patient monitoring and life support
device companies, many of which have significantly greater financial, technical,
research and development and marketing resources than the Company. There can be
no assurance that current OEM customers will not elect to design and manufacture
patient monitoring and system components currently supplied by the
18
19
Company or elect to contract with other OEM suppliers. Any such election by one
or more of such companies could have a material adverse effect on the Company's
business, operating results and financial condition.
In addition, the Company may in the future elect to incorporate in its OEM
products the hardware and software for larger networks and expand the number of
OEM customers with the hardware and software required for real-time
redistribution of information to Remote Viewing Stations for use in specialty
departments of hospitals for which the Company's OEM customers design and sell
their products. Although the Company believes that its OEM customers would not
compete with its Enterprise-wide Monitoring Systems because the Enterprise-wide
Monitoring Systems are sold to hospitals and IHDNs who elect to install larger,
more dispersed systems, the Company could face competition with its OEM
customers to the extent hospitals forego purchasing the Company's facility-wide
Enterprise-wide Monitoring Systems for the smaller departmental systems of its
OEM customers.
Technological Change; Need to Develop New Products. Many aspects of the
medical equipment industry are undergoing rapid technological change, changing
customer needs, frequent new product introductions and evolving industry
standards. Historically, the Company derived substantially all of its revenue
from sales of its Enterprise-wide Monitoring Systems and OEM products. The
Company believes that as the market for these products matures, the Company's
future success will depend upon its ability to develop and introduce on a timely
basis new products and product enhancements that keep pace with technological
developments and that address the increasingly sophisticated needs of acute care
hospitals and IHDNs. In addition, the introduction of competing products
embodying new technologies and the emergence of new industry standards could
render the Company's existing products unmarketable or obsolete. If the Company
is unable to develop and introduce product enhancements and new products in a
timely and cost-effective manner in response to changing market conditions or
customer requirements, or if the Company's new products or product enhancements,
such as SiteLink, do not achieve market acceptance, the Company's business,
operating results and financial condition will be materially adversely affected.
Uncertainty and Consolidation in Healthcare Industry. The healthcare
industry is subject to changing political, economic and regulatory influences
that may affect the procurement practices and operation of healthcare providers.
Many healthcare providers are consolidating to create larger hospitals and
IHDNs. This consolidation reduces the number of potential customers for the
Company's products, and the increased bargaining power of these organizations
could lead to reductions in the amounts paid for the Company's products. These
larger hospitals and IHDNs may concentrate their purchases on a small number of
preferred vendors with whom they have had longstanding relationships. There can
be no assurance that the Company will be able to sell to such hospitals or IHDNs
or that the Company will be able to compete successfully with such vendors. The
impact of these developments in the healthcare industry is difficult to predict
and could have a material adverse effect on the Company's business, operating
results and financial condition.
Government Regulation. The manufacturing, marketing and sales of medical
devices, including the Company's products, are subject to extensive regulation
by numerous governmental authorities. In the United States, the Company's
products are regulated by the Food and Drug Administration. The Company has
received clearance from the FDA to market its current products through the
510(k) premarket notification process. There can be no assurance that a similar
510(k) clearance for any future product or enhancement of an existing product
will be granted or that the process will not be lengthy. If the Company cannot
establish that a product is "substantially equivalent" to certain legally
marketed devices, or if FDA regulatory changes currently under consideration
with respect to arrhythmia software are adopted, the 510(k) clearance procedure
will be unavailable and Company will be required to utilize the longer and more
expensive premarket approval ("PMA") process. Failure to receive or delays in
receipt of FDA clearances or approvals, including the need for extensive
clinical trials or additional data as a prerequisite to clearance or approval,
could have a material adverse effect on the Company's business, operating
results and financial condition. Sales of medical devices and components outside
of the United States are subject to international regulatory requirements that
vary from country to country. There can be no assurance that the Company will be
able to obtain further clearance or approvals for its products or components on
a timely basis or at all, and delays in receipt of, loss of or failure to
receive such approvals or clearances could have a material adverse effect on the
Company's business, operating results and financial condition.
The Company's radio frequency transmitter devices are subject to regulation
by the Federal Communication Commission ("FCC"), and applicable approvals must
be obtained before shipment of such products. The Company believes that all of
its products designated for sale in the United States meet applicable Federal
Communications Commission (FCC) regulations, including US FCC Part 15 for
electromagnetic emissions. The FCC approval process starts with the collection
of test data that demonstrates that a product meets the requirements stated in
Part 15 of the FCC regulations. This data is then included as part of a report
and application that is submitted to the FCC requesting approval. The FCC may
grant or request additional information or withhold approval. Any failure of the
Company's products to conform to governmental regulations or any delay or
failure to obtain required FCC approvals in the future, if any, could cause the
delay or loss of sales of the Company's products and therefore have a material
adverse effect on the Company's business, financial condition and result of
operations.
The Company's proprietary radio frequency (RF) communication products
transmit real-time physiologic information from the patient to the central
surveillance station. These communication products currently operate in three
radio bands: VHF (174 MHz to
19
20
216 MHz, shared with TV channels 7-13); UHF (450 MHz to 470 MHz, shared with
land mobile users); and the 900 MHz radio band (902 MHz to 928 MHz licensed for
Spread Spectrum operation). The majority of the Company's RF products use the
vacant television frequencies in the VHF band. The FCC is requiring all
television stations to implement digital broadcasting transmission for High
Definition Television (HDTV). Major metropolitan areas were required to
implement HDTV by December 31, 1998 and other markets will be required to
implement by December 31, 2006. In order to implement HDTV the FCC has granted
each TV channel an additional 6 MHz channel for digital broadcasting until the
transition period ends, at which time the broadcaster would return one of the
two channels. As TV stations use the additional 6 MHz channel for the digital
broadcasting transition, which may take years, they may overlap into the radio
spectrum which has been used for medical RF applications. Customers of the
Company's lower power RF communication products may begin seeing more
interference in the future. This interference may result in the Company's
hospital biomedical personnel having to re-tune the Company's RF transmitters to
other channels in order to reduce interference. In the event of high
interference the Company's customers may need to purchase equipment to transmit
in the UHF frequency range. In 1998 the FCC expanded the usable UHF frequencies
for medical RF from the licensed 450 MHz to 470 MHz band to the previously
unlicensed 470 MHz to 668 MHz frequency range. With VHF frequency ranges
available for medical RF use potentially becoming more limited and the UHF
frequency ranges expanding, the Company's competitors who have historically
focused their RF products in what was the more limited UHF band, may now have a
competitive advantage as compared to the Company, until such time as the Company
expands its UHF RF product offerings. Any such competitive advantage of the
Company's competitors and any additional development costs associated with
expanding the Company's UHF RF product offerings could have a material adverse
effect on the Company's business, operating results and financial condition.
During 1998 the Company joined a task force created by the American
Hospital Association (AHA) and the FDA called the Medical Telemetry Task Force
(the "Task Force") along with other medical RF users, organizations, and
vendors, including its competitors. The purpose of the Task Force was to respond
to potential interference problems from HDTV, land mobile users and low power
television to wireless patient monitoring devices by recommending both rule
making language and specific spectrum allocation to the FCC. The Task Force's
mission was to identify protected spectrum candidates for future medical
telemetry use, evaluate use and make recommendations to the FCC. As such the
Task Force petitioned the FCC to allocate the UHF 608 MHz to 614 MHz band,
currently reserved for radio astronomy, for medical use on a primary basis. The
Task Force submitted its recommendations to the FCC which then filed a Notice of
Proposed Rule Making (NPRM, FCC docket # 99-182). Once the FCC approves the
rulemaking, which the Company believes is probable, the Company may be at a
disadvantage in the marketplace if one or some of its competitors develop and
introduce RF products in this new band before the Company introduces products in
the new band, resulting in lost or delayed revenues. In addition, the costs of
developing RF transmitter and receiver products is expensive and is diverting
research and development resources from other projects resulting in higher costs
and delayed projects. Any such competitive advantage of the Company's
competitors and any additional development costs associated with expanding the
Company's UHF RF product offerings could have a material adverse effect on the
Company's business, operating results and financial condition. Additionally,
future regulatory changes could significantly affect the Company's operations by
diverting the Company's development efforts, making current products obsolete or
increasing the opportunity for additional competition which could have a
material adverse effect on the Company's business, operating results and
financial condition.
Limited Intellectual Property Protection. The Company relies on a
combination of copyright, trade secret and trademark laws, confidentiality
procedures and contractual provisions to protect its intellectual property. The
Company seeks to protect its software, circuitry documentation and other written
materials under trade secret and copyright laws, which afford only limited
protection. The Company cannot assure that its protective measures for
proprietary rights will be adequate or that the Company's competitors will not
independently develop similar or superior technology, duplicate the Company's
products or otherwise circumvent its intellectual property rights. Although the
Company has never received a claim that its products infringe a third party's
intellectual property rights, there can be no assurance that third parties will
not in the future claim infringement by the Company with respect to current or
future products or proprietary rights. Any such claims, regardless of their
merit, could be time consuming, result in costly litigation, delay or prevent
product shipments or require the Company to enter into costly royalty or
licensing agreements. The impact of any of these developments could have a
material adverse effect on the Company's business, operating results and
financial condition.
Risk of Product Liability Claims. Certain of the Company's products provide
applications that relate to patient physiologic status or other clinically
critical information. Any failure by the Company's products to provide accurate
and timely information could result in product liability and warranty claims
against the Company by its customers or their patients. The Company maintains
insurance against claims associated with the use of its products, but there can
be no assurance that its insurance coverage would adequately cover any claim
asserted against the Company. A successful claim brought against the Company in
excess of its insurance coverage or outside the scope of the Company's insurance
coverage could have a material adverse effect on the Company's business,
operating results and financial condition. The Company in the past had to incur
warranty expenditures for upgrades that had adverse expenses to the periods.
Even unsuccessful claims could result in the expenditure of funds in litigation
and diversion of management time and resources.
20
21
Dependence on Sole Source Components; Component, Assembly & Systems
Obsolescence. Certain of the Company's products utilize components that are
available in the short term only from a single or a limited number of sources,
have been available only on an allocation basis in the past and could be in
scarce supply again in the future. Any inability to obtain components in the
amounts needed on a timely basis or at commercially reasonable prices could
result in delays in product introductions, interruption in product shipments or
increases in product costs, which could have a material adverse effect on the
Company's business, operating results and financial condition until alternative
sources could be developed or design and manufacturing changes could be
completed. In addition, from time to time, certain components, subassemblies and
systems used by the Company are discontinued by manufacturers, requiring the
Company to replace the components, subassembly or system with an equivalent
product or if no such equivalent can be identified to modify and re-validate the
product design. Any inability to obtain such components on a timely basis or at
commercially reasonable prices or to redesign the product in a timely manner
could have a material adverse effect on the Company's business, operating
results and financial condition until alternative sources could be developed or
design and manufacturing changes could be completed.
Risks Associated With Recent Management Changes. In recent years, the
Company has had a number of changes in its management team. These changes
included the Company's Chief Executive Officer in 1997, Vice President, Research
and Development in 1998, and Vice President, Sales and Chief Financial Officer
in 1999. These management changes have caused disruptions in the Company's
day-to-day operations, have interrupted continuity in customer relationships and
have created delays in sales cycles and product release schedules. Although the
Company believes that its existing senior management will be successful in
improving the Company's business, operating results and financial condition,
there can be no assurance that such changes will not have a material adverse
effect on the Company's business, operating results and financial condition in
future periods.
Dependence on Key Personnel. The Company's success depends to a large extent
on its ability to attract and retain key personnel. The loss of the services,
either temporarily or permanently, of any of the members of senior management or
other key employees, particularly in sales and marketing and research and
development, could have a material adverse effect on the Company's business,
operating results and financial condition. In addition, the Company's future
success depends to a large extent on its ability to attract and retain
additional key management, sales and marketing and research and development
personnel. Competition for such personnel is intense. There can be no assurance
that the Company will be successful in attracting and retaining such personnel,
and the failure to do so could have a material adverse effect on the Company's
business, operating results and financial condition.
Volatility of Stock Price. Due to all of the foregoing factors, it is likely
that without advance warning or notice, in some future quarter the Company's
operating results will be below the expectations of market analysts and
investors. This may cause the market price of the Company's common stock to
fall. These risks are impossible to fully determine at present, and should be
considered in evaluating the financial prospects and future growth of the
Company.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company's current policy is to not enter into derivative financial
instruments. Its financial instruments consist of cash and cash equivalents,
short-term investments, trade accounts receivable, accounts payable and accrued
liabilities. The Company considers investments in highly liquid instruments
purchased with an original maturity of three months or less to be cash
equivalents. All of the Company's cash equivalents and short-term investments
are classified as available for sale at December 31, 1999. The Company's
exposure to market risk for changes in interest rates relates primarily to its
short-term investments and short-term obligations, thus, fluctuations in
interest rates would not have a material impact on the fair value of these
securities. The Company does not currently have any significant foreign currency
exposure since it does not transact business in foreign currencies. Due to this,
the Company does not have significant overall currency exposure at December 31,
1999.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
For financial statements, see pages 22 - 33 of this report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
21
22
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholders of VitalCom Inc.,
We have audited the accompanying balance sheets of VitalCom Inc. (the
Company) as of December 31, 1998 and 1999, and the related statements of
operations, stockholders' equity and cash flows for each of the three years in
the period ended December 31, 1999. Our audits also included the financial
statement schedule listed in Item 14. These financial statements and financial
statement schedule are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements and
financial statement schedule based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of VitalCom Inc. at December 31, 1998 and 1999,
and the results of its operations and its cash flows for each of the three years
in the period ended December 31, 1999, in conformity with accounting principles
generally accepted in the United States of America. Also, in our opinion, such
financial statement schedule, when considered in relation to the basic financial
statements taken as a whole, presents fairly, in all material respects, the
information set forth therein.
DELOITTE & TOUCHE LLP
Costa Mesa, California
February 10, 2000
22
23
VITALCOM INC.
BALANCE SHEETS
December 31,
----------------------------
1998 1999
------------ ------------
ASSETS
Current assets:
Cash and cash equivalents ................................................... $ 10,460,810 $ 7,107,420
Short-term investments ...................................................... 5,369,213 5,273,037
Accounts receivable, net of allowance for doubtful accounts and returns
of $350,147 and $346,079 in 1998 and 1999 ................................. 4,615,295 2,309,392
Inventories (Note 2) ........................................................ 1,391,899 1,504,952
Prepaid expenses ............................................................ 140,647 530,833
------------ ------------
Total current assets ................................................ 21,977,864 16,725,634
Property:
Machinery and equipment ..................................................... 1,503,905 1,560,013
Office furniture and computer equipment ..................................... 2,200,732 2,558,815
Leasehold improvements ...................................................... 173,883 181,778
------------ ------------
3,878,520 4,300,606
Less accumulated amortization and depreciation .............................. (2,223,301) (2,831,090)
------------ ------------
Property, net ....................................................... 1,655,219 1,469,516
Other assets (Note 1) ......................................................... 133,894 68,237
Goodwill, net (Note 1) ........................................................ 455,573 423,025
------------ ------------
Total assets .................................................................. $ 24,222,550 $ 18,686,412
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ............................................................ $ 429,987 $ 508,322
Accrued payroll and related costs ........................................... 804,887 959,862
Accrued warranty costs ...................................................... 757,448 516,297
Accrued liabilities (Notes 6 and 7) ......................................... 711,255 568,336
Current portion of capital lease obligations (Note 4) ....................... 24,990 28,796
------------ ------------
Total current liabilities ........................................... 2,728,567 2,581,613
Capital lease obligations, less current portion (Note 4) ...................... 31,552 --
Commitments and contingencies (Note 4)
Stockholders' equity (Notes 6 and 8):
Common stock, including paid-in-capital, $0.0001 par value; 25,000,000 shares
authorized; 8,162,972 shares issued and outstanding at December 31, 1998;
8,281,113 shares issued and 7,917,563 shares outstanding at
December 31, 1999 ......................................................... 37,491,563 37,665,468
Note receivable for common stock sales ...................................... (30,590) (30,590)
Treasury stock, at cost ..................................................... -- (740,154)
Accumulated deficit ......................................................... (15,998,542) (20,789,925)
------------ ------------
Total stockholders' equity .......................................... 21,462,431 16,104,799
------------ ------------
Total liabilities and stockholders' equity .................................... $ 24,222,550 $ 18,686,412
============ ============
See notes to financial statements.
23
24
VITALCOM INC.
STATEMENTS OF OPERATIONS
Years Ended December 31,
--------------------------------------------
1997 1998 1999
------------ ------------ ------------
Revenues ....................................... $ 21,793,555 $ 20,858,926 $ 16,289,617
Cost of revenues ............................... 11,476,974 9,561,471 7,588,487
------------ ------------ ------------
Gross profit ................................... 10,316,581 11,297,455 8,701,130
Operating expenses:
Sales and marketing .......................... 8,562,095 6,793,879 6,128,233
Research and development ..................... 4,815,543 4,697,750 5,729,148
General and administrative ................... 2,535,586 2,158,558 2,357,687
------------ ------------ ------------
Total operating expenses ............. 15,913,224 13,650,187 14,215,068
------------ ------------ ------------
Operating loss ................................. (5,596,643) (2,352,732) (5,513,938)
Other income, net .............................. 972,968 889,621 758,555
------------ ------------ ------------
Loss before provision for income taxes ......... (4,623,675) (1,463,111) (4,755,383)
Provision for income taxes ..................... 26,190 25,200 36,000
------------ ------------ ------------
Net loss ....................................... $ (4,649,865) $ (1,488,311) $ (4,791,383)
============ ============ ============
Net loss per basic and diluted common share .... $ (0.58) $ (0.18) $ (0.60)
============ ============ ============
Weighted average basic and diluted common shares 8,000,982 8,148,085 8,045,998
============ ============ ============
See notes to financial statements.
24
25
VITALCOM INC.
STATEMENTS OF STOCKHOLDERS' EQUITY
For The Years Ended December 31, 1997, 1998 and 1999
Common Stock Treasury Stock Note Receivable
------------------------- ------------------------ for Common
Shares Amount Shares Amount Stock Sales
--------- ------------ -------- ------------ ---------------
Balances, January 1, 1997 7,942,688 $ 36,832,936
Stock options exercised 8,500 6,971
Note receivable for common stock sales 40,000 195,000 $ (195,000)
Cash collections on note receivable 40
Stock issued pursuant to employee
stock purchase plan 47,359 191,218
Net loss
--------- ------------ -------- ------------ ------------
Balances, December 31, 1997 8,038,547 37,226,125 (194,960)
Stock options exercised 28,250 24,549
Note receivable for common stock sales 10,000 30,600 (30,600)
Cash collections on note receivable 10
Cancellation of note receivable for common stock (40,000) (194,960) 194,960
Stock issued pursuant to employee stock
purchase plan 52,703 145,264
Stock issued pursuant to 401(k) plan
employer match 73,472 259,985
Net loss
--------- ------------ -------- ------------ ------------
Balances, December 31, 1998 8,162,972 37,491,563 (30,590)
Stock options exercised 16,750 14,639
Acquisition of treasury stock (363,550) (740,154)
Stock issued pursuant to employee stock
purchase plan 74,334 88,240
Stock issued pursuant to 401(k) plan employer
match 27,057 71,026
Net loss
--------- ------------ -------- ------------ ------------
Balances, December 31, 1999 8,281,113 $ 37,665,468 (363,550) $ (740,154) $ (30,590)
========= ============ ======== ============ ============
Total
Accumulated Stockholders'
Deficit Equity
------------ -------------
Balances, January 1, 1997 $(9,860,366) $26,972,570
Stock options exercised 6,971
Note receivable for common stock sales
Cash collections on note receivable 40
Stock issued pursuant to employee
stock purchase plan 191,218
Net loss (4,649,865) (4,649,865)
------------ -----------
Balances, December 31, 1997 (14,510,231) 22,520,934
Stock options exercised 24,549
Note receivable for common stock sales
Cash collections on note receivable 10
Cancellation of note receivable for common stock
Stock issued pursuant to employee stock
purchase plan 145,264
Stock issued pursuant to 401(k) plan
employer match 259,985
Net loss (1,488,311) (1,488,311)
------------ -----------
Balances, December 31, 1998 (15,998,542) 21,462,431
Stock options exercised 14,639
Acquisition of treasury stock (740,154)
Stock issued pursuant to employee stock
purchase plan 88,240
Stock issued pursuant to 401(k) plan employer
match 71,026
Net loss (4,791,383) (4,791,383)
------------ -----------
Balances, December 31, 1999 $(20,789,925) $16,104,799
============ ===========
See notes to financial statements.
25
26
VITALCOM INC.
STATEMENTS OF CASH FLOWS
Years Ended December 31,
--------------------------------------------
1997 1998 1999
------------ ------------ ------------
Cash flows used in operating activities:
Net loss ............................................. $ (4,649,865) $ (1,488,311) $ (4,791,383)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization ..................... 776,807 735,338 693,027
Provision for doubtful accounts and sales returns . 34,647 79,934 (4,068)
Common stock contribution to 401(k) plan .......... -- 259,985 71,026
Loss on disposal of property ...................... 35,078 1,311 7,004
Changes in operating assets and liabilities:
Accounts receivable ............................... (1,588,353) (842,163) 2,309,971
Inventories ....................................... 1,378,544 420,600 (113,053)
Income tax receivable ............................. 2,874,276 -- --
Prepaid expenses .................................. 91,810 128,815 (390,186)
Other assets ...................................... 88,166 (81,959) 65,657
Accounts payable .................................. (500,228) (155,757) 78,335
Accrued payroll and related costs ................. 322,711 (393,168) 154,975
Accrued warranty costs ............................ 16,864 (210,797) (241,151)
Income taxes payable .............................. 228,294 (21,563) (57,584)
Accrued marketing commitments ..................... (309,377) -- --
Accrued liabilities ............................... (497,897) (620,857) (85,335)
------------ ------------ ------------
Net cash used in operating activities ............. (1,698,523) (2,188,592) (2,302,765)
Cash flows from investing activities:
Purchases of property and equipment .................. (441,661) (283,494) (481,780)
Purchases of short-term investments .................. (6,000,000) -- --
Proceeds from sale of short-term investments ......... -- 630,787 96,176
Proceeds from sale of property ....................... 450 -- --
------------ ------------ ------------
Net cash provided by (used in) investing activities (6,441,211) 347,293 (385,604)
Cash flows from financing activities:
Repayment of long-term debt .......................... (21,538) (24,874) (27,746)
Cash collections on note receivable .................. 40 10 --
Net proceeds from issuance of common stock ........... 198,189 169,813 102,879
Acquisition of treasury stock ........................ -- -- (740,154)
------------ ------------ ------------
Net cash provided by (used in) financing activities 176,691 144,949 (665,021)
Net decrease in cash and cash equivalents .............. (7,963,043) (1,696,350) (3,353,390)
Cash and cash equivalents, beginning of year ........... 20,120,203 12,157,160 10,460,810
------------ ------------ ------------
Cash and cash equivalents, end of year ................. $ 12,157,160 $ 10,460,810 $ 7,107,420
============ ============ ============
Supplemental disclosures of cash flow information:
Interest paid ........................................ $ 31,382 $ 12,136 $ 4,182
============ ============ ============
Income taxes paid .................................... $ 33,025 $ 19,861 $ 26,365
============ ============ ============
Supplemental schedule of noncash transactions:
Notes receivable for stock sales ..................... $ 195,000 $ 30,600 --
Cancellation of note receivable for stock ............ -- $ 194,460 --
See notes to financial statements.
26
27
VITALCOM INC.
NOTES TO FINANCIAL STATEMENTS
1. GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
General and Nature of Operations -- VitalCom Inc. (the Company) provides
computer networks and related communications products that acquire, interpret
and distribute real-time patient monitoring information. The Company's computer
and radio networks acquire physiologic data generated by its own proprietary ECG
monitors and other manufacturers' bedside equipment located throughout a
healthcare facility. The Company's products are sold through a direct sales
force to acute care hospitals and integrated healthcare delivery networks
("IHDNs") and on an Original Equipment Manufacturer ("OEM") basis to patient
monitoring equipment manufacturers primarily located in the United States.
Fair Value of Financial Instruments - The Company's balance sheets include
the following financial instruments: cash and cash equivalents, accounts
receivable, accounts payable, and accrued liabilities. The Company considers the
carrying value of cash and cash equivalents, accounts receivable, accounts
payable, and accrued liabilities in the financial statements to approximate fair
value for these financial instruments because of the relatively short period of
time between origination of the instruments and their expected realization.
Cash Equivalents -- Cash equivalents include highly liquid investments
purchased with an original maturity date of three months or less.
Short-Term Investments - The Company's short-term investments are classified
as available for sale. The Company's short-term investments consist of
commercial paper, money market funds and debt securities. Investments classified
as available for sale are required to be recorded at fair value and any
temporary difference between an investment's cost and its fair value is recorded
as a separate component of stockholders' equity. As of December 31, 1998 and
1999, the fair value of investments approximates investment cost.
Inventories -- Inventories are stated at the lower of weighted average cost
or market. The Company periodically reviews inventory quantities on hand and
provides for excess and obsolete inventory based primarily on current production
requirements and forecasted product demands.
Property -- Property is stated at cost. Depreciation is provided using the
straight-line method and the double declining balance method over the estimated
useful lives of the related assets, generally three to eight years. Leasehold
improvements are amortized over the lesser of the estimated useful lives of the
related improvements or the related lease term.
Long-Lived Assets -- The Company accounts for the impairment and disposition
of long-lived assets in accordance with Statement of Financial Accounting
Standards No. 121 (SFAS No. 121), Accounting for the Impairment of Long-Lived
Assets and for Long-Lived Assets to be Disposed. In accordance with SFAS 121,
long-lived assets to be held are reviewed for events or changes in circumstances
which indicate that their carrying value may not be recoverable. The Company
periodically reviews the carrying value of long-lived assets to determine
whether or not an impairment to such value has occurred and has determined that
there was no impairment at December 31, 1999.
Goodwill -- Goodwill represents the excess purchase cost over the net assets
acquired and is amortized over 20 years using the straight-line method. The
Company periodically evaluates the recoverability of goodwill based on an
undiscounted cash flow analysis related to its product sales and has determined
that there was no impairment of goodwill at December 31, 1999.
Revenue Recognition -- Revenues from both Enterprise-wide Monitoring Systems
and OEM products, which consist of both hardware and software, are recognized
upon shipment if no significant vendor obligations remain and collection of the
related receivable is probable. The Company accounts for insignificant vendor
obligations and post-contract support at the time of product delivery by
accruing such costs, and deferring such revenues and recognizing them ratably on
completion of performance. There is no right of return on sales. Revenues
related to service contracts with customers, which are insignificant, are
deferred and amortized over the terms of the contracts, generally one year.
Warranties -- The Company offers warranties of various lengths depending on
the product and negotiated terms of purchase agreements with its customers. An
estimate for warranty related costs based on historical experience is recorded
at the time of sale.
Software Development Costs -- Development costs incurred in the research and
development of new software products and enhancements to existing software
products are expensed as incurred until technological feasibility has been
established. After technological feasibility is established, any additional
costs would be capitalized in accordance with Statement of Financial Accounting
Standards No. 86, Accounting for the Costs of Computer Software to be Sold,
Leased or Otherwise Marketed. Because the Company believes that its current
process for developing software is essentially completed concurrently with the
establishment of technological feasibility, no costs are capitalized as of
December 31, 1998 or 1999.
27
28
Income Taxes -- The Company accounts for income taxes in accordance with
Statement of Financial Accounting Standard No. 109 (SFAS No. 109), Accounting
for Income Taxes. This statement requires the recognition of deferred tax assets
and liabilities for the future consequences of events that have been recognized
in the Company's financial statements or tax returns. Measurement of the
deferred items is based on enacted tax laws. In the event the future
consequences of differences between financial reporting bases and tax bases of
the Company's assets and liabilities result in a deferred tax asset, SFAS No.
109 requires an evaluation of the probability of being able to realize the
future benefits indicated by such asset. A valuation allowance related to a
deferred tax asset is recorded when it is more likely than not that some
portion or all of the deferred tax asset will not be realized.
Loss Per Share -- Basic and diluted loss per share (EPS) is computed using
the weighted average number of common shares outstanding. Common stock
equivalents were excluded from the calculation of diluted EPS because their
effect was antidilutive.
Comprehensive Loss -- In 1998, the Company adopted Statement of Financial
Accounting Standards No. 130 (SFAS 130), Reporting Comprehensive Income. SFAS
130 establishes standards for the reporting and disclosure of comprehensive
income (revenues, expenses, gains and losses) in a full set of general purpose
financial statements. For the years ended December 31, 1998 and 1999, there was
no difference between comprehensive loss and net loss as reported in the
Company's financial statements.
Recent Accounting Pronouncements -- In June 1998, the FASB issued
Statement of Financial Accounting Standards No. 133 (SFAS 133), Accounting for
Derivative Instruments and Hedging Activities. SFAS 133 establishes accounting
and reporting standards for derivative instruments, including certain derivative
instruments embedded in other contracts, and for derivatives used for hedging
activities. It requires that all derivatives be recognized either as an asset or
liability and measured at fair value. SFAS 133 is required to be adopted
in fiscal year 2001. The Company believes that the application of SFAS 133 will
not have a material impact on the Company's financial statements.
Use of Estimates -- The preparation of financial statements in conformity
with generally accepted accounting principles necessarily requires management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from these estimates.
Certain Risks and Concentrations
Customer Concentrations -- The Company's OEM revenues, which represented
53.7%, 57.9% and 68.6% of the Company's total revenues in 1997, 1998 and 1999
respectively, have historically been concentrated in a small number of OEM
customers. Approximately 45.6%, 46.0% and 60.9% of 1997, 1998 and 1999 total
revenues, respectively, were to three customers. Accounts receivable from these
three customers accounted for 52.0% and 71.5% of the Company's total accounts
receivable at December 31, 1998 and 1999, respectively. The Company performs
limited credit evaluations of its customers' financial condition, and generally
requires no collateral from its customers. The loss of, or a reduction in sales
to, any such OEM customers would have a material adverse effect on the Company's
business, operating results and financial condition. Further, sales of the
Company's OEM products are dependent to a large extent upon the Company's OEM
customers selling patient monitoring devices that include the Company's OEM
products as necessary components. Any inability of such OEM customers to sell
such systems, or any election by such OEM customers not to include the Company's
products as components therein, could have a material adverse effect on the
Company's business, operating results and financial condition.
Supplier Concentration -- Certain of the Company's products utilize
components that are available in the short term only from a single or a limited
number of sources. Certain of these components, such as semiconductor devices,
have been available only on an allocation basis in the past and could be in
scarce supply again in the future. Any inability to obtain components in the
amounts needed on a timely basis or at commercially reasonable prices could
result in delays in product introductions or interruption in product shipments
or increases in product costs, which could have a material adverse effect on the
Company's business, operating results and financial condition until alternative
sources could be developed or design and manufacturing changes could be
completed. Any such design or manufacturing changes or increased costs could
result in delayed shipments and significant expenses in a particular quarter and
therefore could materially adversely affect operating results for any such
quarter or other period.
28
29
2. INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out method) or
market and consist of the following at December 31:
1998 1999
---------- ----------
Raw materials .............. $ 895,145 $ 903,294
Work-in-process............. 47,156 20,047
Finished goods.............. 449,598 581,611
---------- ----------
$1,391,899 $1,504,952
========== ==========
3. REVOLVING LINE OF CREDIT
During the year ended December 31, 1999, the Company had a secured lending
arrangement (the "Agreement") with Silicon Valley Bank, providing for a $5.0
million revolving line of credit agreement bearing interest at either the bank's
prime rate or LIBOR interbank market rate, as selected by the Company. The bank
does not have a security interest in any of the Company's assets until the
Company is borrowing under the line of credit. The Agreement expired on December
31, 1999. In March 2000, the Company and the bank entered into a letter of
commitment for the renewal of the Agreement through March 2001. The Agreement
included restrictive financial covenants that required the Company to maintain
minimum liquidity levels and total liabilities to tangible net worth ratios, as
well as specified annual and quarterly net loss (after taxes) amounts. At
December 31, 1999, there were no borrowings outstanding under the Agreement. As
such, the bank held no security interest in any of the Company's assets.
4. COMMITMENTS AND CONTINGENCIES
The Company leases its facilities and certain equipment under
noncancelable operating leases expiring at various dates through 2005.
Future minimum lease payments under noncancelable operating and capital
leases are as follows:
Capital Operating
Lease Lease
----------- ----------
Year ending December 31:
2000 ..................................... $ 31,552 $ 437,797
2001 ..................................... 467,719
2002 ..................................... 609,613
2003 ..................................... 608,244
2004 ..................................... 621,588
Thereafter ............................... 310,794
---------- ----------
31,552 $3,055,755
==========
Less amount representing interest .......... (2,756)
----------
Present value of minimum lease payments .... 28,796
Less current portion ....................... (28,796)
----------
Capital lease obligations due after one year $ --
==========
Capital leases included in property at December 31, 1998 and 1999, net of
accumulated depreciation, were approximately $74,687 and $59,136, respectively.
The Company's rent expense was $356,265, $349,832 and $375,543 for the years
ended December 31, 1997, 1998 and 1999, respectively.
29
30
5. SEGMENT REPORTING
Utilizing the management approach, the Company has broken down its
business based upon sales through its two distribution channels. The Company
does not allocate operating expenses to these segments, nor does it allocate
specific assets to these segments. Therefore, segment information reported
includes only net sales, cost of sales and gross profit.
Selected information regarding the Company's product sectors is as follows:
Enterprise-wide
OEM Monitoring
Products Products Total
----------- ---------------- -----------
Year ended December 31, 1997
Net Sales ................ $12,540,632 $9,252,923 $21,793,555
Cost of Sales ............ 7,085,457 4,391,517 11,476,974
----------- ---------- -----------
Gross Profit ............. $ 5,455,175 $4,861,406 $10,316,581
=========== ========== ===========
Year ended December 31, 1998
Net Sales ................ $12,071,380 $8,787,546 $20,858,926
Cost of Sales ............ 6,052,828 3,508,643 9,561,471
----------- ---------- -----------
Gross Profit ............. $ 6,018,552 $5,278,903 $11,297,455
=========== ========== ===========
Year ended December 31, 1999
Net Sales ................ $11,144,445 $5,145,172 $16,289,617
Cost of Sales ............ 5,545,323 2,043,164 7,588,487
----------- ---------- -----------
Gross Profit ............. $ 5,599,122 $3,102,008 $ 8,701,130
=========== ========== ===========
6. STOCKHOLDERS' EQUITY
During the year ended December 31, 1997, the Company issued 47,359 shares of
its common stock under its Employee Stock Purchase Plan for net proceeds of
$191,218, and 8,500 shares of its common stock for exercises of stock options
under the 1993 Stock Option Plan for net proceeds of $6,971. The Company also
issued 40,000 shares of its common stock, under interest bearing, non-recourse
notes in the amount of $195,000 and received net proceeds of $40.
During the year ended December 31, 1998, the Company issued 52,703 shares
of its common stock under its Employee Stock Purchase Plan for net proceeds of
$145,264; 73,472 shares of its common stock issued under the VitalCom Employee
Stock 401(k) and Profit Sharing Plan for the employer match valued at $259,985
and 28,250 shares of its common stock for exercises of stock options under the
1993 Stock Option Plan for net proceeds of $24,549. During the year ended
December 31, 1998, the Company also cancelled 40,000 shares of its common stock
that were issued during 1997 under interest bearing, non-recourse notes for
$195,000. The cancellations were due to the purchasers' forfeiting their right
to purchase the shares. In addition, the Company also issued 10,000 shares of
its common stock, under an interest-bearing, nonrecourse note in the amount of
$30,600 and received net proceeds of $10 during 1998.
During the year ended December 31, 1999, the Company issued 74,334 shares of
its common stock under its Employee Stock Purchase Plan for net proceeds of
$88,240; 27,057 shares of its common stock issued under the VitalCom Employee
Stock 401(k) and Profit Sharing Plan for the employer match valued at $71,026
and 16,750 shares of its common stock for exercises of stock options under the
1993 Stock Option Plan for net proceeds of $14,639.
In April 1999, the Company implemented a stock repurchase program whereby up
to 800,000 shares of its Common Stock may be purchased in the open market from
time to time. In October 1999 the Company terminated its stock repurchase
program. The Company repurchased 363,550 shares of Common Stock at a total
aggregate price of $740,154.
30
31
7. 401(k) AND PROFIT-SHARING PLAN
The Company has a contributory profit-sharing plan which covers
substantially all of its employees. Effective July 1, 1993, the Company amended
its profit-sharing plan to include a 401(k) provision (the "401(k) Plan"). The
401(k) provisions in the 401(k) Plan allow eligible employees to contribute up
to 15% of their income on a tax-deferred basis, subject to IRS discrimination
and maximum dollar deferral rules. The Company, at its sole election, may make
matching contributions to the 401(k) Plan. The Board of Directors approved a
discretionary employer matching contribution of $0.50 for each $1.00 the
employee contributes on the first 12% of compensation deposited as elective
contributions, subject to 401(k) Plan limitations and IRS regulations, for
calendar years 1997, 1998 and 1999. The Company's matching contributions vest to
employees at 25% per year for each full year of continuous service. The
Company's 401(k) matching expense was $255,016, $356,006 and $336,116 for the
years ended December 31, 1997, 1998 and 1999, respectively. For the years ended
December 31, 1997 and 1999 the Company's employer matching contribution was made
in cash. For the year ended December 31, 1998 the Company's employer matching
contribution was made in the Company's common stock at the end of each calendar
quarter (see Note 6).
The 401(k) Plan provides for an annual contribution to a self-directed
employee trust in an amount to be determined by the Board of Directors, but
limited to the amount allowable for income tax purposes. Employees may make
annual contributions to the 401(k) Plan of not more than 10% of their annual
compensation. The Company's contributions vest to the employees at 20% for the
first two years and 20% per year for years three through six for each full year
of continuous service, and are allocated based on employee compensation. The
Company had no profit-sharing expense for the years ended December 31, 1997,
1998 and 1999.
8. STOCK BASED COMPENSATION PLANS
At December 31, 1999 the Company had three stock options plans and an
employee stock purchase plan, which are described below. The Company accounts
for these plans in accordance with the provisions of Accounting Principles Board
Opinion No. 25, Accounting for Stock Issued to Employees, and related
Interpretations (APB 25). In October 1995, the Financial Accounting Standards
Board issued Statement of Financial Accounting Standards No. 123 (SFAS 123),
Accounting for Stock-Based Compensation. As permitted by SFAS 123, the Company
has chosen to continue to account for its stock-based compensation plans under
APB 25 and provide the expanded disclosures specified in SFAS 123. No
compensation expense has been recognized for its stock-based compensation plans.
Had compensation cost been determined using the provisions of SFAS 123, the
Company's net loss and loss per share would have been increased to the pro forma
amounts indicated below:
1997 1998 1999
----------- ----------- -----------
Net loss.................................. As reported $(4,649,865) $(1,488,311) $(4,791,383)
Pro forma (5,109,243) (2,728,095) (6,253,899)
Net loss per basic and diluted share...... As reported $(0.58) $(0.18) $(0.60)
Pro forma $(0.64) $(0.33) $(0.78)
For purposes of estimating the compensation cost of the Company's option
grants and employee stock purchase plan in accordance with SFAS 123, the fair
value of each option grant is estimated on the date of grant using the
Black-Scholes option-pricing model with the following assumptions used for
grants in the years 1997, 1998 and 1999, respectively: expected volatility of
52%, 80% and 120%; risk free interest rates of 6.25% for 1997 and 1998 and 6.33%
in 1999; no dividend yield; and expected lives of 10 years for the 1993 Stock
Option Plan and the 1996 Stock Option Plan.
In November 1998, the Company's Board of Directors approved a proposal
allowing the Company's employees and officers to surrender for cancellation any
existing stock option grants and have a new stock option issued for the
equivalent number of shares with one half at a new exercise price of $3.00 per
share and the other half at a new exercise price of $4.00 per share. The new
options vest over the Company's standard four year vesting period, with the
vesting period starting six months later than the vesting commencement date of
the surrendered option. A total of 447,763 options were cancelled with exercise
prices ranging from $4.00 to $6.00 per share. Up to 2,325,885 shares of the
Company's common stock were reserved for issuance under the Option Plan.
The Company has reserved an aggregate of 100,000 shares of Common Stock for
issuance under its 1996 Stock Option Plan (the "1996 Plan") to permit employees
and consultants to the Company to participate in ownership of the Company. The
1996 Plan was adopted by the Board of Directors in October 1996. The 1996 Plan
is administered by a committee consisting of two or more non-employee directors
of the Company. Each option agreement includes a provision requiring the
optionee to consent to the terms of the 1996 Plan. The Option Plan provides for
the grant of nonqualified options.
31
32
The following table summarizes activity under the 1993 Option Plan and 1996
Option Plan, as amended.
Weighted Weighted
Number Average Number of Average
of Price Exercise Options Exercise
Shares Per Share Price Exercisable Price
------------ ----------- --------- ----------- --------
Balance, January 1, 1997.. 715,824 0.60--15.75 5.64 232,035 4.92
Granted................. 1,299,437 3.88-- 5.50 4.64
Exercised............... (8,500) 0.60-- 1.28 0.82
Canceled................ (332,583) 1.28--15.75 6.33
-----------
Balance, December 31, 1997 1,674,178 0.60--15.75 4.74 301,692 5.09
Granted................. 1,642,970 2.63-- 4.44 3.66
Exercised............... (28,250) 0.60-- 1.41 0.87
Canceled................ (1,800,801) 1.28-- 6.00 4.60
-----------
Balance, December 31, 1998 1,488,097 0.60-- 4.00 3.46 343,774 3.46
Granted................. 424,040 1.50-- 3.00 2.29
Exercised............... (16,750) 0.60-- 1.28 0.87
Canceled................ (215,271) 0.60-- 5.72 3.73
-----------
Balance, December 31, 1999 1,680,116 $0.60--$6.00 $3.18 601,094 3.42
===========
At December 31, 1999, 645,769 options were available for grant under the
1993 Option Plan and 1996 Option Plan.
The weighted average fair market value of each option granted under the 1993
Stock Option Plan and the 1996 Stock Option Plan in 1997, 1998 and 1999 was
$4.78, $3.49 and $1.81, respectively.
The following table summarizes information about stock options outstanding
under the 1993 Option Plan and the 1996 Option Plan at December 31, 1999:
Options Outstanding Options Exercisable
-------------------------------------------------- -------------------------------
Weighted Average
Number Remaining Weighted Average Number Weighted Average
Range of Exercise Prices Outstanding Contractual Life Exercise Price Exercisable Exercise Price
- ------------------------ ----------- ---------------- ---------------- ----------- ----------------
$0.60--$2.63............ 274,640 9.1 years $1.81 17,625 $1.05
$3.00--$3.88............ 793,514 8.4 years 3.02 302,713 3.01
$4.00--$6.00............ 611,962 8.2 years 4.00 280,756 4.00
--------- -------
1,680,116 8.4 years $3.18 601,094 $3.42
========= =======
The Company has reserved an aggregate of 300,000 shares of Common Stock for
issuance under its 1996 Employee Stock Purchase Plan (the "ESPP"). The ESPP was
adopted by the Board of Directors in January 1996 and approved by the Company's
stockholders prior to the consummation of the Company's initial public offering
in February 1996. The ESPP is intended to qualify under Section 423 of the
Internal Revenue Code of 1986, as amended, and permits eligible employees of the
Company to purchase Common Stock through payroll deductions of up to 10% of
their compensation provided that no employee may purchase more than $25,000
worth of stock in any calendar year. The ESPP was implemented by an offering
period commencing on February 14, 1996 and ending on the last business day in
the period ending October 31, 1996. Each subsequent offering period (an
"Offering Period") commences on the day following the end of the prior Offering
Period and has a duration of six months. The price of Common Stock purchased
under the ESPP is 85% of the lower of the fair market value of the Common Stock
on the first or last day of each offering period. The ESPP will expire in the
year 2006. In the years ended December 31, 1997, 1998 and 1999 the Company
issued 47,359, 52,703 and 74,334 shares of Common Stock, respectively under the
ESPP for $191,218, $145,264 and $88,240 respectively. At December 31, 1999,
$18,351 had been withheld from employee earnings for stock purchases under the
ESPP.
For purposes of estimating the compensation cost of employees' rights under
the ESPP in accordance with SFAS 123, the fair value of the purchase rights has
been estimated using the Black-Scholes model with the following assumptions used
for 1999; expected volatility of 120%; risk free interest rate of 6.33%;
expected life of six months. The weighted-average fair value of those purchase
rights granted in 1999 was $1.10.
The Company has reserved an aggregate of 60,000 shares of Common Stock for
issuance under its 1996 Director Option Plan (the "Director Plan"). The Director
Plan was adopted by the Board of Directors in February 1996. The Director Plan
provides for the grant of an option to purchase a number of shares of Common
Stock (the "First Option") to be determined by the incumbent Board of Directors
to each non-employee director who first becomes a non-employee director after
the effective date of the Director Plan. Annually, each outside director shall
automatically be granted an option to purchase 4,000 shares (a "Subsequent
Option"), provided he or she is then a non-employee director and, as of such
date, he or she shall have served on the Board for at least the preceding six
months. Each non-employee director will be eligible to receive a Subsequent
Option, regardless of whether such non-employee director was eligible to receive
a First Option. First Options and each Subsequent Option will have a term of ten
32
33
years. One-quarter of the shares subject to a First Option will vest one year
after their date of grant and an additional one-quarter will vest at the end of
each year thereafter, provided that the optionee continues to serve as a
director on such dates. Similarly, one-quarter of the shares subject to a
Subsequent Option will vest one year after the date of the option grant and an
additional one-quarter will vest at the end of each year thereafter, provided
that the optionee continues to serve as a director on such date. The exercise
prices of the First Option and each Subsequent Option will be 100% of the fair
market value per share of the Company's Common Stock on the date of the grant of
the option. At December 31, 1997, 1998 and 1999 there were no options
outstanding and 60,000 shares available for issuance.
9. INCOME TAXES
The provision for income taxes is as follows:
Year Ended December 31,
-----------------------------------------
1997 1998 1999
----------- ----------- -----------
Current:
Federal ................... $ $ $
State ..................... 26,190 25,200 36,000
----------- ----------- -----------
26,190 25,200 36,000
----------- ----------- -----------
Deferred:
Federal ................... (1,861,315) (804,805) (1,496,320)
State ..................... 256,150 (304,624) (221,938)
----------- ----------- -----------
(1,605,165) (1,109,429) (1,718,258)
----------- ----------- -----------
Change in valuation allowance 1,605,165 1,109,429 1,718,258
----------- ----------- -----------
$ 26,190 $ 25,200 $ 36,000
=========== =========== ===========
A reconciliation of the provision for income taxes to the amount of income
tax expense that would result from applying the federal statutory rate (35%) to
loss before provision for income taxes is as follows:
Year Ended December 31,
----------------------------
1997 1998 1999
------ ------ ------
Income tax expense at statutory rate ..... (35.0)% (35.0)% (35.0)%
State tax expense, net of federal benefit 0.6 1.1 0.5
Research and development credits .........
Change in valuation allowance ............ 32.5 32.5 34.3
Other .................................... 2.5 3.1 0.9
----- ----- -----
0.6% 1.7% 0.8%
===== ===== =====
Deferred tax assets and liabilities at December 31 are as follows:
1997 1998 1999
----------- ----------- -----------
Current:
Accrued compensation and related costs $ 219,189 $ 161,281 $ 108,255
Warranty reserves .................... 414,796 324,491 259,887
Sales returns and bad debt allowance . 115,759 127,298 148,260
Inventory reserves ................... 312,191 294,622 272,685
Other ................................ (227,556) (331,465) 69,309
----------- ----------- -----------
834,379 576,227 858,396
Long-term:
Amortization and depreciation ........ (82,569) (170,558) (115,200)
Net operating loss carryforward ...... 1,760,657 2,591,947 4,358,387
Tax credit carryforward .............. 620,519 1,244,799 1,185,273
Deferred state taxes and other ....... (326,183)
----------- ----------- -----------
2,298,607 3,666,188 5,102,277
----------- ----------- -----------
Valuation allowance ................... (3,132,986) (4,242,415) (5,960,673)
----------- ----------- -----------
$ -- $ -- $ --
=========== =========== ===========
As of December 31, 1999, a valuation allowance of $5,960,673 has been
provided based upon the Company's assessment of the future realizability of
certain deferred tax assets, as it is more likely than not that sufficient
taxable income will not be generated to realize these temporary differences.
At December 31, 1999, the Company had federal and state net operating loss
carryforwards of approximately $11.3 million and $6.1 million, respectively,
which will begin expiring in the years 2013 and 2002, respectively. At December
31, 1999, the Company had tax credit carryforwards for federal and state
purposes of approximately $645,000 and $535,000 respectively, which will begin
expiring in the years 2009 and 2012, respectively.
33
34
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Set forth below is certain information concerning the directors of the
Company:
Director
Name of Director Age Position with the Company Since
- ----------------------- --- ------------------------------------------------------ --------
Frank T. Sample 54 President, Chief Executive Officer and Chairman of the 1997
Board of Directors
Jonathan S. Leff 31 Director 1999
Jack W. Lasersohn 47 Director 1995
Timothy T. Weglicki 47 Director 1995
Frank T. Sample has served as a director of the Company and also has served
as its President and Chief Executive Officer since October 1997. In February
1998, Mr. Sample was appointed Chairman of the Board. From August 1997 to
October 1997, Mr. Sample served as Executive Vice President at IDX Systems
Corporation, a leading provider of information technology to the healthcare
industry. From December 1990 to July 1997, when PHAMIS, Inc., a provider of
patient-centered medical record information systems, was merged into IDX Systems
Corporation, Mr. Sample served as President and Chief Executive Officer of
PHAMIS, Inc. He is a director of IDX Systems Corporation. Mr. Sample holds a
B.B.A. in Business Administration from Cleveland State University.
Jonathan S. Leff has served as a director of the Company since September
1999. Since 1996, Mr. Leff has been employed as a Managing Director of E.M.
Warburg Pincus & Co., LLC, a private investment firm. He is currently a director
of Visible Genetics, Inc. and Intermune Pharmaceuticals, Inc., as well as
several privately-held companies . Mr. Leff holds a BA degree from Harvard
University and an MBA from Stanford University.
Jack W. Lasersohn has served as a director of the Company since June 1995.
He has been a General Partner of The Vertical Group, L.P., a private venture
capital and investment management firm, since its formation in 1989 by former
principals of F. Eberstadt & Co., Inc. From 1981 to 1989, he was a Vice
President and later a Managing Director of the venture capital division of F.
Eberstadt & Co., Inc. Mr. Lasersohn also serves as a director of Cardiothoracic
Systems, Inc., UroQuest Medical Corporation and Massimo Corporation and of a
number of privately held healthcare companies. He holds a B.S. and a M.A. in
Physics from Tufts University, and a J.D. from Yale University.
Timothy T. Weglicki has served as a director of the Company since June 1995.
Since December 1993, he has been principally employed as a Managing Member of
ABS Partners, L.P., the General Partner of ABS Capital Partners, L.P., a private
equity fund. Prior to that date, he was principally employed as a Managing
Director of Alex. Brown & Sons Incorporated where he established and headed its
Capital Markets Group. Mr. Weglicki holds an M.B.A. from the Wharton Graduate
School of Business and a B.A. from Johns Hopkins University. Mr. Weglicki is a
director of ElderTrust, a healthcare Real Estate Investment Trust and a number
of privately held healthcare companies.
BOARD MEETINGS AND COMMITTEES
The Board of Directors of the Company held a total of six (6) meetings
during fiscal 1999. No director attended fewer than 75% of the meetings of the
Board of Directors and committees thereof, if any, upon which such director
served. The Board of Directors has an Audit Committee and an Executive
Compensation Committee.
The Audit Committee was established in June 1995 and is responsible for
reviewing the results and scope of the audit and other services provided by the
Company's independent auditors. The Audit Committee currently consists of
directors Timothy T. Weglicki, Jack W. Lasersohn, and Jonathan S. Leff. The
Audit Committee met five (5) times in fiscal 1999.
The Executive Compensation Committee and the Option Plan Committee were
combined into one committee in 1997 (the "Compensation Committee"). The
Compensation Committee is responsible for the administration of the Company's
1993 Stock Option Plan, the Company's 1996 Stock Option Plan, the Company's 1996
Director Option Plan and any future option plans of the Company, as well as
determining which persons are to be granted options under such plans and the
number of shares subject to such options. The Compensation Committee consists of
directors Jonathan S. Leff and Timothy T. Weglicki. The Compensation Committee
met seven (7) times in fiscal 1999.
DIRECTOR COMPENSATION
Directors of the Company do not receive any fees for serving as such, nor do
any directors receive any fees for serving on any committee of the Board of
Directors. Directors are reimbursed by the Company for their out-of-pocket
expenses in connection with
34
35
attending any board or committee meeting. In addition, the directors participate
in the Company's 1996 Director Option Plan (the "Director Plan"). The Director
Plan provides for the grant of an option to purchase a number of shares of
Common Stock to be determined by the incumbent Board of Directors to each
non-employee director, and each outside director is automatically granted an
option to purchase 4,000 shares of Common Stock each year, provided he or she is
then a non-employee director and he or she has served on the Board of Directors
for at least the preceding six months. The fist options and each subsequent
option have terms of ten years. One quarter of the shares subject to a first
option will vest one year after its date of grant and an additional one-quarter
will vest at the end of each year thereafter, provided that the optionee
continues to serve as a director. Similarly, one-quarter of the shares subject
to a subsequent option will vest one year after the date of grant and an
additional one-quarter will vest at the end of each year thereafter, provided
that the optionee continues to serve as a director. The exercise price of such
options will be 100% of the fair market value per share of the Company's Common
Stock on the date of grant.
EXECUTIVE OFFICERS
In addition to Mr. Sample, the following persons were executive officers of
the Company as of March 15, 2000:
Name Age Position
---- --- --------
Warren J. Cawley ... 59 Vice President, Product Management
John R. Graham ..... 54 Vice President, Corporate Alliances
Stephen E. Hannah... 41 Vice President, Research and Development
Cheryl L. Isen ..... 39 Vice President, Corporate Communications
Patric L. Wiesmann.. 38 Vice President, Sales
Warren J. Cawley, Vice President Product Management -- Mr. Cawley has
served as Vice President, Product Management since July 1996. From 1989
through June 1996, Mr. Cawley served as Vice President, Direct Sales for the
Company. From 1985 through 1989, Mr. Cawley served as Vice President, OEM Sales
for the Company. Prior to 1985, Mr. Cawley served in various sales and
management capacities at several medical device companies. Mr. Cawley holds an
M.B.A. degree and a B.S. degree from the University of Southern California.
John R. Graham, Vice President Corporate Alliances -- Mr. Graham has served
as Vice President, Corporate Alliances since January 1999 and Vice President,
OEM Sales of the Company from 1989 through 1998. Prior to joining the Company in
1989, he acted as a consultant and held various positions at a number of
healthcare organizations and technology-based companies, including serving as
President and Chief Executive Officer of a medical device company. Mr. Graham
holds an M.S. degree in Bioengineering from Columbia University and a B.S.E.E.
degree from Northeastern University.
Stephen E. Hannah, Vice President, Research and Development -- Mr. Hannah
joined the Company in December 1998 as Vice President, Research and Development.
Prior to joining the Company, Mr. Hannah led Product Development, Systems
Engineering at Sony Trans Com Inc. Prior to Sony, Mr. Hannah developed hardware
and software products and managed large development projects at Hughes Aircraft
Company. Mr. Hannah holds a B.S. degree in Computer Engineering from the
University of Michigan.
Cheryl L. Isen, Vice President, Corporate Communications -- Ms. Isen joined
the Company in January 1998 as Senior Director of Corporate Communications and
was promoted to Vice President in January 1999. Prior to joining the Company,
Ms. Isen served as Senior Director of Corporate Communications at PHAMIS, Inc.,
which merged with IDX Systems in 1997, where she was responsible for
company-wide communications. Prior to PHAMIS, Inc., Ms. Isen was Manager of
Marketing Communications for the Target Marketing Services division of TRW. Ms.
Isen holds a B.A. degree in Journalism and Marketing from San Diego State
University.
Patric L. Wiesmann, Vice President, Sales -- Mr. Wiesmann joined VitalCom in
March 1999 as Vice President, Sales. Prior to joining the Company, Mr. Wiesmann
served as Vice President of Sales and Marketing/Business Development at Mackie
Designs, Inc where Mr. Wiesmann managed worldwide sales and marketing, product
management and sales administration. Prior to Mackie, Mr. Wiesmann was Vice
President of Sales and Marketing at Lang Manufacturing Company and Baxter
Healthcare Corporation. Mr. Wiesmann holds a B.A. degree in Biology and
Economics from the University of Puget Sound in Tacoma, Washington.
35
36
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth the compensation earned by (i) the Company's
Chief Executive Officer, and (ii) the four most highly compensated other
executive officers of the Company (collectively, the "Named Executive Officers")
for services rendered in all capacities to the Company during the fiscal years
ended December 31, 1997, 1998 and 1999:
SUMMARY COMPENSATION TABLE
Long-term
Other Compensation Awards
Annual --------------------------
Annual Compensation Compensation Securities All Other
--------------------------- ------------ Underlying Compensation
Name and Principal Position Year Salary($)(4) Bonus($)(1) (2)($) Options(#) $(5)
--------------------------- ---- ------------ ----------- ------ ---------- ------------
Frank T. Sample .................... 1999 $291,764 $ -- -- -- $2,592
President, Chief Executive Officer 1998 294,958 20,000 -- -- 2,112
and Chairman of the Board 1997 38,434 50,000 -- 780,000 --
Warren J. Cawley.................... 1999 146,977 -- -- 7,500 3,229
Vice President, Product Management 1998 144,810 -- -- 8,500 1,842
1997 153,500 25,000 -- 30,000 1,800
Patric L. Wiesmann.................. 1999 144,461(6) 18,000 -- 100,000 275
Vice President, Sales 1998 -- -- -- -- --
1997 -- -- -- -- --
John R. Graham...................... 1999 145,651 19,391 -- 10,000 2,070
Vice President, Corporate 1998 145,000 18,764 -- 12,000 1,325
Alliances 1997 138,692 35,000 -- 40,000 1,162
Shelley B. Thunen................... 1999 156,054 -- -- 15,000 318
Vice President, Finance and Chief 1998 155,000 10,000 -- 15,000 696
Financial Officer (3) 1997 153,068 45,000 -- 60,000 682
- ----------
(1) Represents amounts paid or accrued under the Company's Management Bonus Plan
for which senior management is eligible. The amount of a particular
employee's bonus varies depending on salary level, position with the Company
and the operating results of the Company.
(2) In accordance with the rules of the Securities and Exchange Commission,
other compensation in the form of prerequisites and other personal benefits
has been omitted in those cases where the aggregate amount of such
prerequisites and other personal benefits constituted less than the lesser
of $50,000 or 10% of the total annual salary and bonus for the Named
Executive Officer for such year.
(3) Ms. Thunen stepped down from her position as Vice President, Finance and
Chief Financial Officer in January 2000.
(4) Amounts include contributions paid by the Company under its 401(k) and
Profit Sharing Plan.
(5) Represents premiums paid by the Company on a life insurance policy for the
benefit of the Named Executive Officer.
(6) Based on an annual salary of $150,000 commencing on March 8, 1999.
36
37
OPTION GRANTS IN FISCAL 1999
The following table sets forth information with respect to stock option
grants to each of the Named Executive Officers during the year ended December
31, 1999.
Individual Grants
---------------------------------------------------------------------
Number of % of Total
Securities Options/SARs
Underlying Granted to
Options/SARs Employees in Exercise or Base
Name Granted(#)(1) Fiscal Year(%) Price($/Sh) Expiration Date
- --------------------- ------------- -------------- ---------------- ---------------
Frank T. Sample ...... -- -- -- --
Warren J. Cawley .... 7,500 1.8% $1.875 06/03/2009
Patric L. Wiesmann ... 80,000 18.9% $3.000 03/08/2009
20,000 4.7% $1.875 09/27/2009
John R. Graham ....... 10,000 2.4% $1.875 06/03/2009
Shelley B. Thunen .... 15,000 3.5% $1.875 06/03/2009
- ----------
(1) All of these stock option grants were pursuant to the Company's 1993 Stock
Option Plan, as amended, and are subject to the terms of such plan. These
options were granted at exercise prices equal to the fair market value of
the Common Stock as determined by the Board of Directors of the Company on
the date of grant. Unless otherwise indicated, options granted vest as to
25% of the shares subject to the option on the first anniversary of the date
of grant and as to 6.25% of the shares subject to the option quarterly
thereafter.
AGGREGATED OPTION EXERCISES IN FISCAL 1999
AND FISCAL YEAR-END OPTION VALUES
The following table sets forth information with respect to exercises of
stock options during the year ended December 31, 1999 by each of the Named
Executive Officers, the number of options held at year end and the aggregate
value of the "in-the-money" options held at December 31, 1999.
Number of Securities Value of Unexercised
Shares Underlying Options at In-the-Money Options at
Acquired on Value Year-End(#) Exercisable/ Year-End Exercisable/
Name Exercise(#) Realized($) Unexercisable Unexercisable(1)($)
- -------------------------- --------------- ----------- ------------------------ -----------------------
Frank T. Sample........... -- -- 341,250/438,750 $0/$0
Warren J. Cawley.......... -- -- 39,475/27,642 $6,116/$0
Patric L. Wiesmann........ -- -- 15,000/85,000 $0/$0
John R. Graham............ -- -- 45,759/37,358 $6,116/$0
Shelley B. Thunen......... -- -- 67,262/58,738 $0/$0
- ----------
(1) The closing price of the Company's Common Stock on December 31, 1999 was
$1.6875 per share.
COMPENSATION COMMITTEE INTERLOCKS
The Compensation Committee was formed in December 1997 and the members of
the Compensation Committee are Mr. Leff and Mr. Weglicki. Neither of these
individuals, and Patrick T. Hackett, Mr. Leff's predecessor on the Compensation
Committee, was at any time during the fiscal year ended December 31, 1999, or at
any other time, an officer or employee of the Company. No member of the
Compensation Committee of the Company's Board serves as a member of the board of
directors or compensation committee of any entity that has one or more executive
officers serving as a member of the Company's Board of Directors or Compensation
Committee.
37
38
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
On March 15, 2000, 7,978,596 shares of the Company's Common Stock were
issued and outstanding and held of record by approximately 37 stockholders.
The following table sets forth certain information known to the Company
regarding the beneficial ownership of the Common Stock as of March 15, 2000 as
to (i) each person known by the Company to own beneficially more than five
percent of the outstanding shares of Common Stock, (ii) each director of the
Company, (iii) each Named Executive Officer (as defined above) of the Company
and (iv) all directors and executive officers as a group. Unless otherwise
indicated, the address for each stockholder is care of VitalCom Inc., 15222 Del
Amo Avenue, Tustin, California 92780.
Shares Beneficially Owned
-------------------------
Name and Address Number Percent
---------------- -------- -------
Warburg, Pincus Ventures, L.P. (1).................................... 3,915,181 46.4%
466 Lexington Avenue, 10th Floor
New York, NY 10017
ABS Capital Partners, L.P. (2)........................................ 1,057,062 12.5
One South Street
Baltimore, MD 21202
Vertical Fund Associates, L.P. (3).................................... 539,582 6.4
18 Bank Street
Summit, NJ 07901
Frank T. Sample (4)................................................... 427,260 5.1
Jonathan S. Leff (5).................................................. 3,915,181 46.4
Jack W. Lasersohn (6)................................................. 755,782 9.0
Timothy T. Weglicki (7)............................................... 1,057,062 12.5
Warren J. Cawley (8)................................................. 110,053 1.3
John R. Graham (9).................................................... 190,167 2.3
Shelley B. Thunen (10)................................................ 91,052 1.1
Patric L. Wiesmann (11)............................................... 20,000 *
Cheryl L. Isen (12)................................................... 16,920 *
Stephen E. Hannah (13)................................................ 14,005 *
All executive officers and directors as a Group (9 persons) (14)...... 6,506,430 77.1
- ----------
Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. Shares of Common Stock subject to options,
warrants and convertible notes currently exercisable or convertible, or
exercisable or convertible within 60 days of April 1, 2000 are deemed
outstanding for computing the percentage of the person holding such option but
are not outstanding for purposes of computing the percentage of any other
person. Except as indicated by footnote, and subject to community property laws
where applicable, the persons named in the table above have sole voting and
investment power with respect to all shares of Common Stock shown as
beneficially owned by them.
* Less than one percent of the outstanding Common Stock.
(1) The sole general partner of Warburg, Pincus Ventures, L.P. ("Ventures") is
Warburg, Pincus & Co., a New York general partnership ("WP"). E.M. Warburg,
Pincus & Co., LLC, a New York limited liability company ("EMW LLC"),
manages Ventures. The members of EMW LLC are substantially the same as the
partners of WP. Lionel I. Pincus is the managing partner of WP and the
managing member of EMW LLC and may be deemed to control both WP and EMW
LLC. WP has a 15% interest in the profits of Ventures as the general
partner, and also owns approximately 1.5% of the limited partnership
interests in Ventures. Jonathan S. Leff, a director of the Company, is a
Managing Director and a member of EMW LLC and a general partner of WP. As
such, Mr. Leff may be deemed to have an indirect pecuniary interest (within
the meaning of Rule 16a-1 under the Exchange Act) in an indeterminate
portion of the shares beneficially owned by Ventures and WP. See Note 5
below.
(2) The sole general partner of ABS Capital Partners, L.P. ("ABS Capital") is
ABS Partners, L.P. ("ABS Partners"). Timothy T. Weglicki is a general
partner of ABS Partners.
(3) The sole general partner of Vertical Fund Associates, L.P. ("Vertical
Fund") is The Vertical Group, Inc. ("Vertical"). Jack W. Lasersohn is a
Managing Director of Vertical.
(4) Includes 390,000 shares issuable upon exercise of vested options within 60
days of April 1, 2000.
38
39
(5) All of the shares indicated as owned by Mr. Leff are owned directly by
Ventures and are included because of his affiliation with Ventures. Mr.
Leff disclaims "beneficial ownership" of these shares within the meaning of
Rule 13d-3 under the Exchange Act. See Note 1 above.
(6) Of the shares indicated as owned by Mr. Lasersohn, 216,200 are owned
directly by Vertical Life Sciences, L.P., of which Vertical is the sole
general partner, and 539,582 are owned directly by Vertical Fund, and all
of such shares are included because of Mr. Lasersohn's affiliation with
those entities. As such, Mr. Lasersohn may be deemed to have an indirect
pecuniary interest in an indeterminate portion of the shares beneficially
owned by Vertical Life Sciences, L.P., Vertical Fund and Vertical. Mr.
Lasersohn disclaims "beneficial ownership" of these shares within the
meaning of Rule l3d-3 under the Exchange Act.
(7) All of the shares indicated as owned by Mr. Weglicki are owned directly by
ABS Capital and are included because of his affiliation with that entity.
As such, Mr. Weglicki may be deemed to have an indirect pecuniary interest
in an indeterminate portion of the shares beneficially owned by ABS Capital
and ABS partners. Mr. Weglicki disclaims "beneficial ownership" of these
shares within the meaning of Rule 13d-3 under the Exchange Act.
(8) Includes 41,883 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000.
(9) Includes 49,009 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000.
(10) Includes 72,392 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000. Ms. Thunen stepped down as Vice President,
Finance and Chief Financial Officer in January 2000, thus her 91,052 shares
beneficially owned have been excluded from the total executive officers and
directors shares beneficially owned as of March 15, 2000.
(11) Includes 20,000 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000.
(12) Includes 16,920 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000.
(13) Includes 14,005 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000.
(14) Includes 522,768 shares issuable upon exercise of stock options exercisable
within 60 days of April 1, 2000 and 3,915,181, 1,057,062, 539,582 and
216,200 shares owned directly by Ventures, ABS, Vertical Fund and Vertical
Life Sciences, L.P., respectively. See notes 5, 6 and 7 above.
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT
Section 16(a) of the Exchange Act ("Section 16(a)") requires the Company's
executive officers and directors, and persons who own more than ten percent of a
registered class of the Company's equity securities to file reports of ownership
and changes in ownership with the Securities and Exchange Commission ("SEC") and
the National Association of Securities Dealers, Inc. Executive officers,
directors and greater than ten percent stockholders are required by SEC
regulation to furnish the Company with copies of all Section 16(a) forms they
file. Based solely on its review of the copies of such forms received by it, or
written representations from certain reporting persons, the Company believes
that during fiscal 1999, all reporting persons complied with filing requirements
applicable to them.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
In October 1997, the Company entered into an employment agreement with Mr.
Sample in connection with his appointment as President and Chief Executive
Officer. The agreement provides for a three-year employment term, subject to
early termination in the event of the death or disability of Mr. Sample or
otherwise provided therein. The Company may terminate Mr. Sample's employment
with or without "Just Cause" (as defined therein), but in the event such
termination is without "Just Cause" Mr. Sample will be entitled to receive
severance pay at his then current salary for a period of twelve months following
such termination.
39
40
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) The following documents are filed as part of this Form 10-K:
(1) Financial Statements. The following Financial Statements of
VitalCom Inc. and Independent Auditors' Report are filed as part
of this report. See pages 22 to 33.
Independent Auditors' Report
Balance Sheets at December 31, 1998 and 1999
Statements of Operations for the years ended December 31,
1997, 1998 and 1999
Statements of Stockholders' Equity for the years ended
December 31, 1997, 1998 and 1999
Statements of Cash Flows for the years ended December 31,
1997, 1998 and 1999
Notes to Financial Statements
(2) Financial Statement Schedules. The following financial statement
schedule of VitalCom Inc. is filed as part of this report and
should be read in conjunction with the Financial Statements of
VitalCom Inc.
SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS
Balance at Charged to Balance
Beginning Costs and End
Description of Period Expenses Deductions of Period
- ----------- --------- ---------- ---------- ---------
Allowance for Doubtful Accounts and Sales Returns:
December 31, 1997 .............................. $235,566 $ 34,647 $ -- $270,213
December 31, 1998 .............................. 270,213 79,934 -- 350,147
December 31, 1999 .............................. 350,147 -- (4,068) 346,079
Balance at Charged to Balance
Beginning Costs and End
Description of Period Expenses Deductions of Period
- ----------- --------- ---------- ---------- ---------
Allowance for Excess and Obsolete Inventory:
December 31, 1997 .............................. $583,319 $288,130 $(142,711) $728,738
December 31, 1998 .............................. 728,738 263,640 (304,651) 687,727
December 31, 1999 .............................. 687,727 32,389 (83,597) 636,519
All other schedules are omitted because they are inapplicable
or because the requested information is shown in the financial
statements of the Company or in the related notes thereto.
(b) Reports on Form 8-K:
None
40
41
(c) Exhibits
Exhibit
No. Description of Exhibit
------- ----------------------
3.1 Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.(1)
3.2 Amended and Restated Bylaws of the Registrant, as currently in effect.(1)
4.1 Specimen Common Stock Certificate.(1)
4.2 Form of Voting Agreement among the Registrant, Warburg, Pincus Ventures, L.P., ABS Capital
Partners, L.P. and Donald W. Judson.(1)
10.1 Registrant's 1993 Stock Option Plan, as amended, and forms of agreement thereunder.(7)
10.2 Registrant's 1996 Employee Stock Purchase Plan.(8)
10.3 Lease dated July 28, 1995 between Catellus Development Corporation as Landlord and Registrant as
Tenant.(1)
10.4 Warburg Securities Purchase Agreement dated as of June 1, 1995 by and among the Registrant,
Warburg, Pincus Ventures, L.P., ABS Capital Partners, L.P., Vertical Fund Associates, L.P.,
Vertical Partners, L.P. and BT Capital Partners, Inc.(1)
10.5 Form of Indemnification Agreement between the Registrant and its executive officers and
directors.(1)
10.6 Form of Employment Agreement between the Registrant and certain of its executive officers.(1)
10.7 Form of Employee Severance Agreement with certain of the Registrant executive officers.(1)
10.8 Registrant's 1996 Director Option Plan.(1)
10.9 Registrant's 1996 Stock Option Plan and related agreements.(9)
10.10 Promissory Note Secured by Deed of Trust dated October 17, 1996 of David L. Schlotterbeck in
favor of the Registrant.(2)
10.11 Loan Agreement between the Registrant and Silicon Valley Bank dated February 26, 1993, as
amended through August 6, 1996.(1)
10.12 Common Stock Purchase Agreement dated July 14, 1998 between the Registrant and Irwin & Browning,
Inc.(10)
10.13 Silicon Valley Bank Amendment to Loan Agreement.(6)
10.14 Second amendment to lease dated August 30, 1999 between Catellus Finance 1, L.L.C. as Landlord
and Registrant as Tenant.(*)
23.1 Independent Auditors' Consent.(*)
24.1 Power of Attorney (Included on page 42 hereof).
27 Financial Data Schedule.(*)
- ----------
(*) Filed herewith.
(1) Incorporated by reference to the Registrant's Registration Statement on
Form S-1 (File No. 333-00268-LA) in the form in which it was declared
effective on February 13, 1997.
(2) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended September 30, 1996.
(3) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1997.
(4) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1997.
(5) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended September 30, 1997.
(6) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1999.
(7) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 333-47173).
(8) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 333-67109).
(9) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 333-33901).
(10) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1998.
41
42
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
VitalCom Inc.
By: /s/ Frank T. Sample
-------------------------------------
Frank T. Sample
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Frank T. Sample as his attorney-in-fact, with
full power of substitution, for him in any and all capacities, to sign any and
all amendments to this Report on Form 10-K, and to file the same, with exhibits
thereto and other documents in connection therewith, with the Securities and
Exchange Commission, hereby ratifying and confirming all that of said
attorney-in-fact, or his substitute or substitutes, may do or cause to be done
by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant on March 28, 2000 in the capacities indicated.
Signature Title
- --------- -----
/s/ Frank T. Sample Chairman of the Board,
- ---------------------------- President and Chief Executive Officer
Frank T. Sample (Principal Executive and Accounting Officer)
/s/ Jonathan S. Leff Director
- ----------------------------
Jonathan S. Leff
/s/ Jack W. Lasersohn Director
- ----------------------------
Jack W. Lasersohn
/s/ Timothy T. Weglicki Director
- ----------------------------
Timothy T. Weglicki
42
43
EXHIBIT INDEX
Sequentially
Exhibit Numbered
No. Description of Exhibit Pages
------- ---------------------- ------------
3.1 Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.(1)
3.2 Amended and Restated Bylaws of the Registrant, as currently in effect.(1)
4.1 Specimen Common Stock Certificate.(1)
4.2 Form of Voting Agreement among the Registrant, Warburg, Pincus Ventures, L.P., ABS Capital
Partners, L.P. and Donald W. Judson.(1)
10.1 Registrant's 1993 Stock Option Plan, as amended, and forms of agreement thereunder.(7)
10.2 Registrant's 1996 Employee Stock Purchase Plan.(8)
10.3 Lease dated July 28, 1995 between Catellus Development Corporation as Landlord and Registrant as
Tenant.(1)
10.4 Warburg Securities Purchase Agreement dated as of June 1, 1995 by and among the Registrant,
Warburg, Pincus Ventures, L.P., ABS Capital Partners, L.P., Vertical Fund Associates, L.P.,
Vertical Partners, L.P. and BT Capital Partners, Inc.(1)
10.5 Form of Indemnification Agreement between the Registrant and its executive officers and
directors.(1)
10.6 Form of Employment Agreement between the Registrant and certain of its executive officers.(1)
10.7 Form of Employee Severance Agreement with certain of the Registrant executive officers.(1)
10.8 Registrant's 1996 Director Option Plan.(1)
10.9 Registrant's 1996 Stock Option Plan and related agreements.(9)
10.10 Promissory Note Secured by Deed of Trust dated October 17, 1996 of David L. Schlotterbeck in
favor of the Registrant.(2)
10.11 Loan Agreement between the Registrant and Silicon Valley Bank dated February 26, 1993, as
amended through August 6, 1996.(1)
10.12 Common Stock Purchase Agreement dated July 14, 1998 between the Registrant and Irwin & Browning,
Inc.(10)
10.13 Silicon Valley Bank Amendment to Loan Agreement.(6)
10.14 Second amendment to lease dated August 30, 1999 between Catellus Finance 1, L.L.C. as Landlord
and Registrant as Tenant.(*)
23.1 Independent Auditors' Consent.(*)
24.1 Power of Attorney (Included on page 42 hereof).
27 Financial Data Schedule.(*)
- ----------
(*) Filed herewith.
(1) Incorporated by reference to the Registrant's Registration Statement on
Form S-1 (File No. 333-00268-LA) in the form in which it was declared
effective on February 13, 1997.
(2) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended September 30, 1996.
(3) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1997.
(4) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1997.
(5) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended September 30, 1997.
(6) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1999.
(7) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 333-47173).
(8) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 333-67109).
(9) Incorporated by reference to the Registrant's Registration Statement on
Form S-8 (File No. 333-33901).
(10) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1998.